What did Rua Bioscience Limited announce?

Rua Bioscience Limited (NZX: RUA) filed “Rua Releases Annual Report for Year Ended 30 June 2026” with NZX on 22 September 2026, as an annual report announcement.

From the announcement:“The Annual Report provides an overview of Rua's FY26 performance and progress, including the continued development of its international distribution channels and expansion into new markets.”
When was it filed?
22 September 2026
Where is the original?
NZX announcement
Rua Bioscience Limited logo

Rua Releases Annual Report for Year Ended 30 June 2026

Annual Report22 September 2026RUAHealthcare

ANNUAL REPORT


FOR PUBLIC RELEASE

NZX Limited

Wellington


Monday, 2 2 September 2026


Rua Bioscience releases Annual Report for the Year Ended 30 June 2026

• FY26 total revenue increased 53% to $2.9m with revenue from customers up

71% to $2.6m

• International market presence expanded in key markets of Australia, New

Zealand, Germany, the United Kingdom and Czechia, alongside the

establishment of Rua genetics in Canada.


• Subsequent to year end, Rua secured its largest export agreement to date

in the United Kingdom expected to generate NZ$10 million in revenue over its

initial two-year term.



FY26 FY25 Change

Revenue from customers $2,581,533 $1,511,282 71% Increase

Total revenue $2,898,010 $1,899,733 53% Increase

Loss before net financing costs $(3,074,881) $(3,297,806) 7% Reduction

Loss before tax $(3,359,660) $(3,455,662) 3% Reduction


Tairawhiti, New Zealand – Rua Bioscience (NZX: RUA) has today released its Annual

Report for the 12 months ended 30 June 2026 (FY26), highlighting a year of strong

commercial progress and continued execution of Rua’s export-led strategy.

FY26 saw Rua deliver significant revenue growth, strengthen its position in established

international markets and move to secure its largest export agreement to date in the

United Kingdom. These developments demonstrate increasing customer demand for
Rua’s New Zealand-grown medicinal cannabis products and the growing reach of its

capital-efficient approach to international growth.

The Annual Report provides an overview of Rua's FY26 performance and progress,

including the continued development of its international distribution channels and

expansion into new markets. Rua’s strategy remains anchored in its differentiated

Tairāwhiti genetics, strategic cultivation partnerships and targeted international

distribution.

The Annual Report is attached and is also available on Rua’s website:

www.ruabio.com/annual-report.

Financial Results

Rua's financial performance was previously outlined with the release of preliminary

unaudited results on 28 August 2026. Revenue from customers grew 71% to $2.6m (FY25:

$1.5m), driving total revenue up 53% to $2.9m (FY25: $1.9m). Loss before tax reduced 3%

to $3.36m (FY25: $3.46m); excluding financing costs and one-off inventory impairments,

the loss narrowed from $3.30m to $3.07m.




The release of audited financial statements was delayed while the Board completed

further funding through the previously announced Convertible Note facility. For further

0.3

1.9

2.9

FY24FY25FY26

Total Revenue NZ$mill

information and context please refer to the Going Concern Note (Note 2(f) ) in the
Financial Statements.


The Directors continue to believe Rua is well positioned for growth, supported by

continued shareholder backing, an expanding international sales pipeline and Rua's

newly signed United Kingdom distribution agreement.


Delivering on strategy

FY26 demonstrated continued execution of Rua’s strategy to build a sustainable

international medicinal cannabis business through differentiated genetics, strong market

partnerships and effective routes to market. Rua strengthened its position in Australia,

where sales revenue and margin almost doubled, grew in Aotearoa New Zealand,

expanded its product offering in Germany, entered the United Kingdom and Czechia and

completed its first export of live cannabis clones to Canada.

The progress made during

FY26 created the platform for Rua’s significant post-year-end expansion into the United

Kingdom.


“FY26 shows that Rua's export-led strategy is translating into real commercial

momentum,” said Anna Stove, Board Chair. “Our position in established markets has

strengthened, we have opened important new growth pathways in the United Kingdom

and Canada, and our home market continues to grow. We are grateful for the continued

support of our shareholders, whose backing has enabled Rua to convert this expanding

market access into tangible commercial progress.”


Subsequent events

Following the FY26 balance date, Rua confirmed two further developments that are

expected to support continued growth into FY27:


United Kingdom: Rua signed a sales and distribution agreement with a leading UK clinic

chain in July 2026, expected to generate NZ$10 mill in revenue over its initial two-year

term.


Aotearoa New Zealand: regulatory approval was received for five further products from

the New Zealand Medicinal Cannabis Agency in July 2026, supporting Rua's expanded

product range.


Further capital requirements
To support its ongoing growth, Rua will continue to require additional capital as sales

expand across its international markets. The Board continues to work with key

shareholders and advisors on funding options to support the Group's working capital and

inventory requirements.


Outlook

Rua's focus for FY27 is on continuing sales growth across its established markets of New

Zealand, Australia, Germany and the United Kingdom, while building out new revenue

streams from emerging markets including Czechia and Canada. Sales are anticipated to

maintain an upward trajectory through FY27, supported by ongoing investment in new

product development.


Alongside this commercial progress, Rua remains committed to its kaupapa of delivering

social impact in Tairawhiti and beyond. In FY26, Rua's Compassionate Access

Programme continued to support up to 52 patients each month, and the company

awarded 14 undergraduate scholarships to local rangatahi through its Scholarship

Programme.


“Rua's momentum continues to build,” said Paul Naske, Chief Executive Officer. “We are

confident in the opportunities ahead across our export markets and remain committed

to building long-term, sustainable value for our shareholders, our people and our

communities.”


ENDS




For more information, please visit www.ruabio.com or contact:

Paul Naske

Chief Executive Officer

+64 (21) 445 154

www.ruabio.com

---

Rua Bioscience
Annual Report 2026

Te Ripoata a Ta u

2
Maori founded and based in Te Tairawhiti, Rua

Bioscience Limited strengthened its position in

the global medicinal cannabis market.

In FY26, we built upon our strategy of growing into

our key markets to create sustainable value for

patients, communities and shareholders.

Kua pakari ake te tunga o te kamupene o Rua

Bioscience Limited, kaupapa Maori no te Tairawhiti,

hei kaiarahi i roto i nga makete rautini i te ao whanui.

I te tau piuta 26, i whai hua nga whainga a ta matou

rautaki, kia tipu ake matou i roto i nga makete

whakahirahira, kia whai hua hoki nga turoro, nga

hapori me nga kaipupuri hea.

―

Tolaga Bay - Aotearoa

―

Germany

3
Local

Global

4
Nau mai haere mai e nga Iwi

katoa, anei nga korero mo

Rua Bioscience

Welcome to Rua Bioscience

We are proud to share Rua Bioscience’s

FY26 Annual Report.

Within this report, we provide a

progress update on the key milestones

achieved over the past 12 months,

outline our financial performance and

highlight the developments within our

key global markets.

We demonstrate how we are delivering

on our strategy and creating tangible

commercial results as we continue

to work towards sustainable revenue

under our highly scalable, export-led

approach.

We will also provide insight into our

local initiatives, including our impact

and sustainability programmes,

showing how we continue to prioritise

our people and our rohe (region).

Rua is committed to reporting openly

and honestly on our performance,

providing information that is clear

and easily understood. If you have

any feedback on this Annual Report,

please email info@ruabio.com

5Rua Bioscience ― Annual Report 2026
―

Sunrise over Mangaoporo

Photo credit: Eruera Walker

6
Anna Stove

Chair

Tony Barclay

Chair Audit, Finance and Risk

Nga korero a nga Ringatohu

Directors’ statement

The Directors are pleased to present Rua Bioscience Limited's

Annual Report and consolidated financial statements for the

year ended 30 June 2026.

The Directors are not aware of any circumstances since the end of

the year that have significantly affected or may significantly affect

the operations of Rua Bioscience. This Annual Report is dated 22

September 2026 and is signed on behalf of the Board by:

―

Sunrise over Hikurangi

Photo credit: Josie McClutchie

7Rua Bioscience ― Annual Report 2026
Rarangi korero

Table of contents

Directors’ statement6

Achievements at a glance8

Board of Directors12

Results at a glance9

Chair & CEO’s report10

Our people15

Senior management14

Rua’s strategy for global impact20

Financial commentary23

Global progress24

Rua's key markets26

Impact programmes30

Towards sustainability36

Financial statements38

Shareholder information78

Who we are16

Our values18

Contact directory90

8
Mawhiti mai ki nga whakatutukitanga

Achievements at a glance

Subsequent activity

Secured Rua’s largest export agreement to date, a

United Kingdom sales and distribution agreement

expected to generate more than NZ$10 million in

revenue over its initial two-year term.

Increased revenue from customers by 71%

to $2.58 million.

Strengthened commercial relationships with

leading clinic chains in Australia.

Raised $2.3 million of new shareholder capital to

strengthen commercial operations and support

continued execution of Rua’s strategy.

Expanded Rua’s product portfolio in Aotearoa

New Zealand, supporting continued revenue and

market-share growth.

Completed Rua’s first export of live cannabis

clones to Canada, establishing a platform for the

future commercialisation of Rua’s unique genetics

in one of the world’s largest cannabis markets.

9Rua Bioscience ― Annual Report 2026
Mawhiti mai ki nga hua nui

Results at a glance

Revenue from customers

$2.6m ↑ 71% on FY25

Cash and investments

$534K

Total revenue and other income

$2.9m ↑ 53% on FY25

Loss before tax

$3.4m ↓ 3% on FY25

Net assets

$4.3m

10
Te ripoata a te Heamana

Chair & CEO’s Report

We want to thank our shareholders and

investors for their continued support.

Our December 2025 rights offer

sought to raise $2 million and was

oversubscribed, with applications of

$2.3 million, 14% above target.

FY26 marked a clear shift for Rua: The foundations

established in FY25 began to translate into

commercial traction across our markets. Revenue

and market share grew in key markets, we entered

new territories and secured our largest export

agreement to date. We now operate across six

countries, creating a more diversified platform

and reducing reliance on any single market. That

breadth matters: It gives Rua more options for

growth and greater resilience as individual markets

move at different speeds.

Australia: We continued to grow market share and

deepen our clinic partnerships in Australia this

year, even as the regulator's industry-wide review

weighed on prescribing volumes across the market.

Gaining ground while others contracted is a strong

signal of our products, our partnerships, and

our team.

United Kingdom: This market is experiencing very

strong growth, and subsequent to year-end, Rua

signed a landmark export agreement: a sales

and distribution agreement with one of the UK's

largest medicinal cannabis clinic and distribution

businesses. The agreement is a significant

endorsement of our strategy to bring Rua's unique

genetics to international markets, and is expected

to generate revenues of approximately NZ$10mill

over its initial term. It gives Rua immediate access

to an established clinic network and pharmacy

relationships, creating a strong platform to

accelerate our growth across the UK.

Germany: The world's largest medicinal cannabis

market saw constraints on imports in the first half

of the year in addition to a review by the German

government, which softened wholesale demand.

We expect only modest changes to emerge from

the review and see this as part of the continued

maturation and development of the market rather

than a change in underlying demand.

Aotearoa, New Zealand: Our domestic market

remained smaller in scale but steady and stable.

Our local patient base is central to Rua's identity,

and we have seen a continued broadening of

patient access and growth of market share.

Maintaining a strong presence in our home market

remains an important part of Rua's commercial

and social purpose.

Czechia: Capitalising on regulatory reform, we

launched our first product in September 2025 via

distribution partner Motagon. Whilst this is a small,

early-stage market, we expect to see revenue build

through FY27. The overall market will continue to

grow as prescribers and patients become familiar

with the new medicinal cannabis access scheme,

providing Rua with an early position in a market

with significant potential for future growth.

FY26 showed us that the

foundations built in FY25 can

translate into commercial

traction.

We saw this in the growth

of established markets, the

opening of new territories, and

the largest export agreement

in Rua's history.

Just as importantly, we learned

that international growth

requires more than entering a

market. It depends on strong

local partnerships, reliable

supply, regulatory capability

and disciplined execution.

These capabilities are

becoming an increasingly

important part of Rua's

competitive advantage as

we operate across multiple

jurisdictions. The breadth

of our market portfolio also

reduces reliance on any single

market and creates more

pathways for future growth

and resilience.

11Rua Bioscience ― Annual Report 2026
Canada: In April 2026 Rua completed the first

known legal export of live cannabis genetics from

New Zealand, shipping four varieties as clones

to Apollo Green in Ontario; a first for both Rua

and for New Zealand, and our first foothold in

Canada's regulated adult-use market estimated at

$5-6 billion annually. This milestone demonstrated

both the quality and commercial potential of our

genetics and our ability to navigate complex cross-

border regulatory requirements. It represents an

important new opportunity for Rua as we continue

to build a portfolio of international markets.

The year has also reinforced some important

lessons for management and the Board.

Market entry alone does not create a successful

business. Sustainable growth depends on strong

local partnerships, reliable supply, regulatory

execution and disciplined capital allocation.

Commitment to Impact

Rua's commercial progress does not change our

commitment to impact. In FY26, our Compassionate

Access Programme continued to support 52 patients

each month, with dedicated places for palliative

care. This remains an important part of our purpose.


The Scholarship Programme has continued to

expand, with 67 rangatahi supported since the

Programme’s inception and over $90,000 awarded

in collaboration with Trust Tairawhiti and external

partners. Our Internship Programme is also building

capability and creating employment pathways

in this emerging industry. In FY26 a dedicated

cultivation intern has transitioned into full time

employment and now leads the mushroom

cultivation programme for the Tū Wairua

psilocybin collaboration.

For Rua, commercial success and impact are not

competing priorities. They are complementary

parts of the business we are building. These

initiatives show how commercial progress can

translate into greater access, capability and

opportunity at home. As Rua grows, we intend

the connection between business performance

and local impact to strengthen.

Looking Ahead

FY27 begins from a stronger and more diversified

platform, with established sales in Germany,

Australia and Aotearoa New Zealand, a growing

position in Czechia, a first foothold in Canada, and

a landmark UK agreement.

Our focus is now on execution: converting these

opportunities into recurring revenue, deepening

established markets and scaling with discipline

on capital and capability as we build

long-term value.

Rua's waka is built for the journey ahead. With the

team, partnerships, and strategy in place, we are well

positioned to navigate the opportunities ahead with

confidence and purpose.

To our shareholders, thank you for your continued

belief in our vision. To our team, thank you for your

dedication, adaptability, and mahi. We are proud

of the progress Rua has made and confident in the

foundations we have built for our next stage of growth.

―

Anna Stove

Chair

―

Paul Naske

Chief Executive

12
Te Poari Ringatohu

Board of Directors

Rua Bioscience’s Board of

Directors are deeply invested

in the Rua kaupapa. They

possess a wealth of domestic

and international business,

pharmaceutical and strategic

expertise.

Co-founder of Rua, Panapa

established New Zealand’s

first tertiary training course

for cannabis cultivation

via the Eastern Institute of

Technology. From Ruatorea,

with a degree in management,

Panapa is a co-founder of

numerous social enterprises

and holds governance

roles across a wide range

of for-profit and charitable

organisations. Panapa lives

in Tairawhiti and focuses

on developing economic

opportunities alongside

his people. He has been

a Director of Rua since its

inception in October 2017.

Panapa Ehau

Executive Director,

Co-Founder

Kaiwhakau / Ringatohu

Ngati Uepohatu, Ngati Porou

Anna Stove

Chair

Heamana

Anna has been a Director of

Rua since 2019 and was elected

Board Chair in April 2023. Anna is

an experienced leader with more

than 25 years’ global executive

and board experience across

healthcare, biotechnology and

regulated scientific sectors. She

has a strong track record guiding

organisations through growth,

commercial transformation

and complex regulatory

environments, underpinned by

deep commercial and scientific

literacy. Her executive career

spans senior leadership roles

across Asia Pacific and Europe,

culminating in her appointment

as New Zealand General

Manager for GlaxoSmithKline.

Anna has held a number of

significant governance roles

including Chair of TAB NZ, Chair

of Global Women NZ, Director

of Medicines New Zealand, and

Vice Chair of Shooting Star

Children's Hospice in London.

She is also a Director of Pacific

Edge Ltd.

13Rua Bioscience ― Annual Report 2026
Teresa brings extensive

governance and senior

management experience across

listed companies, state-owned

entities, family enterprises

and privately held businesses,

spanning consumer packaged

goods, agriculture, horticulture,

IT, regulatory bodies and

agri-research. Teresa's prior

boards include Zespri, Food

Standards Australia and New

Zealand, Firstlight Foods and

AgResearch. On the boards she

serves, Teresa is recognised for

her role in elevating business

strategy, marketing and the

consumer as a driver of business

transformation, refreshing

innovation pipelines and

embedding high standards of

compliance and governance.

She has chaired People &

Remuneration Committees as

well as Audit & Risk Committees,

served as a member of

Innovation Committees,

contributed to CEO succession

and worked collaboratively with

colleagues to sharpen strategic

clarity and prioritise major

initiatives. Teresa joined the

Board in August 2022.

Tony brings over 30 years’

experience in business and 25

years healthcare experience.

Tony was CFO at medical

device company Fisher & Paykel

Healthcare from the time of

separation from Fisher & Paykel

Appliances in 2001 until retiring

from full-time employment in

2018. Prior to Fisher & Paykel

Healthcare Tony worked for

PriceWaterhouse and Arnott’s

Biscuits in finance roles. Tony is

an Independent Director and

Chairman of Baymatob PTY

Limited and an Independent

Director and Chair of the Audit

and Risk Committee of Pacific

Edge Ltd. Tony holds a BCom

from the University of Otago

and is a Chartered Accountant

and a member of the New

Zealand Institute of Directors

and INFINZ. Tony’s significant

leadership experience in the

healthcare sector is valued by

the Board and he has proven

himself to be a strong and

capable contributor. Tony

joined the Board in May 2023.

Kale Ponoho joined Rua as a

board observer during FY24.

With his placement now

complete during FY26, we

look forward to welcoming a

new observer as we continue

supporting the development

of future Maori governance

leaders.

As part of our commitment

to social impact, Rua

reserves a board observer

seat for participants of He

Tukutuku Koiora, a tikanga-

led governance programme

that accelerates talented

Maori professionals into

future governance roles.

The programme combines

online and in-person learning,

mentoring, and an 18-month

placement in a governance

role. Rua is pleased to support

this programme.

Teresa Ciprian

Non-Executive Director

Ringatohu Whakatu Pu

Tony Barclay

Non-Executive Director

Ringatohu Whakatu Pu

Kale Ponoho

Board Observer

Kaimatakitaki Poari

Ngāpuhi

14
Liam Walker

Virtual Chief

Financial Officer

Apiha Kaiwhakahaere Putea

Mai Tawhiti

Our Senior Management Team is charged with delivering

operational excellence, executing Rua’s strategy, and leading

Rua’s expansion into global medicinal cannabis markets.

Nga pou Matua

Senior Management

Paul has held a range of

leadership positions in business

strategy and development,

including roles as General

Manager of Corson Grain and

as a Business Unit Manager

at Fletcher Building. Paul has

been overseeing Rua’s topline

business operations since the

beginning of 2019 and has

been vital to the design and

efficient execution of Rua’s

global strategy. His knowledge

of the commercial environment

ensures Rua’s alignment with

the business needs of our global

clients. Paul was promoted

to the role of Chief Executive

Officer in February 2023.

Liam is a BDO Partner based

in Auckland. He joined BDO in

2007. Liam provides proactive

financial advice to a wide range

of clients in the healthcare,

construction, freight and logistics

industries. He delivers a blend

of commercial, financial and

strategic knowledge to identify

a business’ impediments, and

solutions to help them grow. A

strong believer in innovation, he

aims to help clients spend more

time on their business, rather

than in it. Liam plays an active

role as vCFO with a number of

his clients, including Rua.

Emma has been with Rua

since October 2019 and was

instrumental in establishing the

GMP standards and agreements

necessary for Rua to operate.

Emma holds a Masters of

Science (MSc) in Forensic

Chemistry from the University

of Strathclyde, Scotland as well

as a Bachelor of Science (BSc)

majoring in Medicinal Chemistry

from the University of Auckland.

Emma came to Rua from ESR

where she was part of the

Forensic Drug Chemistry Team.

Paul Naske

Chief Executive Officer

Kaiwhakahaere Matua

Emma McIldowie

Quality and

Corporate Affairs

Kaiwhakahaere Kounga Me Nga

Take Rangatopu

15Rua Bioscience ― Annual Report 2026
We’re a unique collection of dual

forces; science and nature, land and

people, commerce and community,

modern innovation and ancestral

wisdom. These connections bring

balance and integrity to our team

and business.

Our vision, to create cannabis-based

medicines that make a difference,

inspires and guides the work of our

team every day.

Te tira o Rua

Our people

16
Te pakihi o Rua

Who we are

Rua is a pioneering medicinal cannabis business with

a growing international presence. Maori-founded in

Ruatorea, we provide medicinal cannabis products for

local and export markets. We remain focused on creating

intergenerational social impact in Te Tairawhiti.

Our purpose

To deliver cannabis-based medicines that change people’s lives.

How we will achieve our purpose

Build a financially sustainable business that inspires the next

generation, creates intergenerational social impact for our people,

and supplies cannabis-based medicines around the world.

―

Pete Sollitt - Ngati Porou

Grower Technician

17Rua Bioscience ― Annual Report 2026

18
Nga uara

Our values

Since the beginning, Rua has been guided by

our four key values that shape our identity

and purpose. They are the foundation of how

we operate, the measure of our integrity and

the compass that guides us for our people,

communities and the world.

Ponotanga

We respect diversity. We have integrity in all relationships.

Whakawhanaungatanga

We collaborate for success.

Mauitanga

We do “business as unusual”. We celebrate learning and curiosity, innovation

and courage. We have hope for the future.

Oranga

We work for healthy whanau and healthy whenua. We prioritise the

wellbeing of our customers, staff, family and the wider industry.

19Rua Bioscience ― Annual Report 2026
―

Kevin Pewhairangi

Pharmacist

20
Te rautaki o Rua hei

whakaaweawe i te ao

Rua’s strategy for global impact

The strategy we set in FY24, and demonstrated

through FY25, remains the foundation of Rua’s

approach. In FY26, our focus shifted to disciplined

execution: applying the model consistently while

adapting to the opportunities and challenges

of each market. Our aim is to build a financially

sustainable medicinal cannabis business with the

longevity to create lasting value for shareholders,

our community and our people.

Rua’s focused, capital-efficient model continues

to provide a strong foundation for sustainable

growth. We concentrate our resources on the

areas where Rua can create the greatest value -

developing differentiated genetics, understanding

and responding to customer and patient needs, and

building effective routes to market. Cultivation and

manufacturing are undertaken by trusted, best-

in-class partners, giving Rua access to specialist

capability without the need to replicate capital-

intensive infrastructure. This approach keeps

us agile and enables us to pursue new market

opportunities as they emerge, while directing our

investment to the areas that matter most.

In FY26, this approach supported continued growth

across our established markets and expansion into

Czechia and Canada. Subsequent to year-end,

Rua signed its largest export agreement to date

in the United Kingdom. We enter FY27 focused on

disciplined execution, converting market access

into sustainable revenue growth and continuing to

expand in a capital-efficient way.

1. Genetics

2. Cultivation

3. Manufacturing

4. Distribution

21
―

Rau Hiwa

Premium Export Product

Sourced under New Zealand's unique regulatory framework, which permits the

inclusion of legacy genetics in the medicinal cannabis sector, Rau Hiwa T23 pays

homage to the safekeepers of distinctive cannabis genetics in our community

and Aotearoa New Zealand.

22
22

―

Rua Flower

23Rua Bioscience ― Annual Report 2026
23

Nga korero mo nga putea

FY26 Financial commentary

In FY26 Rua achieved significant growth, building on

our international network and regulatory expertise.

Income

Rua’s total revenue and other income was recorded as $2.90m (FY25

$1.90m). FY26 revenue was driven particularly by growth in Australia

and New Zealand. The revenue from customers increased to $2.58m

(FY25 $1.51m).

Loss for the year

Rua’s loss before tax for the year to 30 June 2026 was $3.36m (FY25

$3.46m). Excluding financing costs and one-off inventory impairments,

the loss narrowed from $3.30m to $3.07m.

Balance sheet

Rua’s balance sheet at the end of FY26 reflects a year of deliberate

investment in growth. The company’s net asset position eased

slightly year on year as capital raised during the period was deployed

into inventory and working capital to support sales growth. During

FY26, Rua raised $2.3 million of new shareholder capital through a

combination of private placements and a rights offer. This shareholder

support has helped fund the inventory and working capital required to

support growth across multiple markets.

Rua continues to apply a disciplined, capital-efficient approach to

growth. With sales momentum building across multiple markets, the

company enters FY27 focused on converting that momentum into

sustained revenue growth and a strengthening financial position.

24
Kokiri ki te ao

Global progress

From the beginning, Rua has believed that global

growth is essential to creating local impact. FY26

was a year of expansion. During the year we

increased our global footprint in the markets of

United Kingdom, Czechia and Canada which are

all markets with significant opportunity for Rua.

United

Kingdom

Canada

Czechia

Germany

25Rua Bioscience ― Annual Report 2026
United KingdomSecured significant export agreement with one of the leading

clinic chains subsequent to year end.

GermanyExpanded product portfolio and supply options, at a time of change

within the industry.

CzechiaSecured early market entry through agreement with Motagon;

first products launched in early FY26.

AustraliaAlmost doubled revenue through close relationships with key

clinic chains.

Aotearoa New ZealandSignificantly grew market share and increased our product portfolio.

CanadaExported the first live clones to Apollo Green to establish a genetic bank

providing further options for distribution and revenue.

Australia

Aotearoa


New Zealand

26
Australia

Australia is the world's second largest

medicinal cannabis market, estimated at $1.4

billion, with telemedicine clinics continuing

to dominate prescribing and a growing shift

toward more developed product formats. It

remains a highly competitive market and the

regulator's ongoing review has created some

caution among prescribers and pharmacists.

There is no formal timeline for the review’s

conclusion. Rua delivered strong growth in

Australia in FY26, with sales revenue and

margin almost doubling due to the strength

of consistent clinic relationships. Although

the outcome of the regulatory review remains

uncertain and the competitive landscape

continues to drive industry consolidation,

Rua's focus remains on portfolio

management and improving margins.

―

Sydney Harbour

Nga makete

Rua’s key markets

Germany
Germany remains the world's largest medicinal cannabis market, with

telemedicine clinics now dominant and the market estimated at $2 billion.

A government review of medicinal cannabis regulations, combined with market

oversupply of products, made for a challenging trading environment in FY26;

even so, Rua expanded its product range with New Zealand grown genetics

and progressed early discussions with large clinic chains. Rua expects only

minor amendments to the regulations to be confirmed, with limited impact

on patient demand, and anticipates growth in FY27 as these clinic relationships

convert to sales. Recent supplier negotiations have also reduced delivered

cost by close to 50%, which is expected to support improved margins.

―

Brandenburg Gate in Berlin, Germany

27Rua Bioscience ― Annual Report 2026

28
United Kingdom

The United Kingdom is currently the fastest

growing medicinal cannabis market, with

prescription volumes doubling over the

past year and a population of 63 million

pointing to considerable further growth

from a market currently estimated at $400

million. FY26 was a year of relationship-

building for Rua in the UK, culminating in

a signed sales and distribution agreement

with a leading clinic chain in July 2026,

expected to deliver in the order of NZ$10

million in sales over two years. Rua expects

significant growth as it builds out this new

agreement and looks forward to working

with New Zealand cultivators to bring Rua's

unique genetics into the UK market.

Czechia

Czechia is a small, early-stage medicinal

cannabis market currently estimated

at $10 million, but regulatory change

from April 2025 - allowing General

Practitioners to prescribe medicinal

cannabis - has opened considerable

growth potential in a population roughly

twice the size of New Zealand's. Rua

entered the Czech market in FY26

through its distribution partner, Motagon,

achieving first revenues in the country

and establishing a foundation of clinic

relationships for further growth. Rua

expects further, modest revenue from

Czechia in FY27 as the market continues

to develop.

―

Prague

29Rua Bioscience ― Annual Report 2026
Aotearoa New Zealand

Aotearoa New Zealand is Rua's home market, where strong

relationships with patients and shareholders continue to support

our growth in a market currently estimated at $60 million. Rua

increased both market share and revenue in New Zealand in

FY26, introducing new products including a medical vaporising

device. Rua received approval for five further products from the

regulator in July 2026. With telehealth clinics becoming more

prevalent, Rua expects sales revenue and margin in New Zealand

to continue to grow as this expanded product range reaches

more patients.

―

East Cape Lighthouse

30
Nga hotaka whakaawe

Impact programmes

31Rua Bioscience ― Annual Report 2026
Impact areas Target

EnvironmentalIdentify ways to mitigate our emissions, with a particular focus on

travel emissions.

Set emissions reduction targets and work towards achieving them.

Complete our fifth annual GHG emissions report.

Continue to improve the quality of data captured for GHG emissions

reporting while simplifying data collection.

Investigation into renewable energy utilisation, in particular Solar at

Ruatorea facility.

SocialContinue providing scholarships, further education and training

opportunities to local rangatahi, aligned with Rua's kaupapa.

Expand Rua’s Compassionate Access Programme, which provides fully

funded medicinal cannabis products to those in Te Tairawhiti who are

most in need.

Monitor worker health and wellbeing, and support staff in managing

their health and wellness.

Continue to contribute to cannabis law and regulations reform.

Continue developing opportunities for NZ cannabis genetics.

GovernanceConduct an annual review of the Board to ensure alignment of

capabilities with the skills matrix.

Further strengthen the Board’s approach to ethical governance and

set objectives for diversity in the management team and Board.

Continue commitment to Aspiring Maori Directors Development

Programme.

Global Growth, Local Impact

For Rua, creating intergenerational impact is

more than a commitment, it is the heart of who

we are. Through our Compassionate Access and

Impact Programmes, we ensure equitable access

and future opportunity. Guided by our ESG and

sustainability commitments, Rua is growing

responsibly - competing on a global scale while

delivering meaningful outcomes for our people,

our rohe and the environment.

―

Photo credit: Josie McClutchie

32
Rua’s Impact Programmes invest in people

and place; building capability, confidence and

opportunity across our rohe. In a region where

career and development opportunities can be

limited, our science-focussed programmes help

whanau and rangatahi see what is possible,

connect with new opportunities and build skills

that contribute to the future of Tairawhiti.

Our approach is built around four E’s:

Exposure, Education, Experience and Employment

– creating opportunities to

see, learn, do and ultimately contribute.

E tipu e rea - Nga kaupapa whakaora a Rua

Growing our future

Exposure

This starts with giving rangatahi exposure to

education and career possibilities, both close to

home and further afield. Rua supports local kura to

take tauira out of the rohe to connect with scientists

and professionals in research organisations and

tertiary institutions. Rua also hosts educational

visits at our cultivation facility in Ruatorea, sparking

curiosity and showing rangatahi what science and

industry can look like in practice.

Education

The Rua Scholarship Programme is a grassroots

investment in the education of young people from

our rohe. By reducing financial barriers to tertiary

study, it gives rangatahi the opportunity to step

beyond the familiar, experience new places and see

themselves in different careers, while building the

skills and confidence to return home and contribute

to their whanau and rohe.

Experience

Rua Internships give locals hands-on experience

in science and biotechnology, building specialist

skills and opening up opportunities in sectors

that may otherwise be out of reach. Interns

work alongside our team in cultivation, research

support and regulatory compliance, gaining

practical experience, as Rua works to strengthen

the skills and capability of our people.

Employment

Our ultimate goal is to turn early investment

in education and experience into greater

employability. By building skills, confidence and

real-world experience, we are helping people

add value across industries in Tairawhiti and

strengthening the talent, capability and future

workforce of our rohe.

Rua Bioscience ― Annual Report 202633
Home Grown

– Peyton Van Der Lem

Ngata College’s 2026 Head Student shows what

can happen when opportunity meets aspiration.

Through Rua’s Exposure programme, Peyton

has taken part in careers excursions to learning

institutions in Wellington and Hawke’s Bay,

opening her eyes to possibilities beyond the coast.

She has also drawn on the knowledge of Rua’s

cultivators and the Ruatorea facility to support her

Year 13 Biology and Physics NCEA assignments,

turning local industry exposure into real academic

experience.

Peyton’s next step is already in view. In 2027, Rua

hopes to support her into Veterinary Studies at EIT

Hawke’s Bay through the Education programme

as a Rua Scholarship recipient – moving from

exposure, to education, and towards a future she

can bring home.

Home Grown

– Mahuta Morice

From intern to industry leader.

In 2024, Rua welcomed Mahuta into its Intern

Programme, giving him his first experience in the

biotech and cultivation sectors.

During his three-month internship, Mahuta

demonstrated commitment and potential

and was invited to join Rua’s Capability and

Advancement Programme. He took on greater

responsibility and, at its completion, was offered

full-time employment with Rua.

Mahuta now leads the mushroom cultivation

programme for Tū Wairua – a groundbreaking

kaupapa at the forefront of its field.

His story shows what can happen when local

talent is given the opportunity, support and

platform to grow: Exposure leads to Education,

Education creates Experience, and Experience

can lead to Employment and lasting contribution

back to our rohe.

Our Impact Since 2020

Since the programme began in 2020, and with the support of Trust Tairawhiti and external partners from

2021, Rua has:

• Awarded more than $90,000 in scholarship funding to 67 recipients

• Funded 8 school trips, giving rangatahi exposure to tertiary and research opportunities

• Supported 3 internships, with one progressing into full-time employment at Rua

These opportunities are more than financial support. They are an investment in people – helping rangatahi

and whanau build knowledge, confidence, skills and connections that strengthen the future of Tairawhiti.

34
He Putanga Aroha

Compassionate access programme

In Aotearoa New Zealand, medicinal cannabis is not a subsidised

medicine, which means it is out of reach for many.

In 2022 Rua launched its Compassionate Access Programme as a

commitment to reduce barriers to healthcare and make a meaningful

difference in the lives of people who could benefit from medicinal

cannabis.

Since 2025, with the generous support of Trust Tairawhiti, an anonymous

donor and our supply partners, Rua has filled the prescriptions for

medicinal cannabis of 52 patients each month, who would otherwise

be unable to afford it. We make places available specifically for people

receiving palliative care, so that those who need support at this time in

their lives, can access it.

Our Compassionate Access Programme reflects our commitment to

healing and equality, striving to eliminate health disparities and create

a more inclusive and compassionate healthcare environment.

35Rua Bioscience ― Annual Report 2026
Tū Wairua

Leading psychedelic medicine

Rua's involvement in the groundbreaking Tū Wairua initiative gives

us the opportunity to advance our objectives and aspirations for

our community.

Tū Wairua is a research project that is developing a culturally-

appropriate approach to the use of indigenous psilocybin-containing

mushrooms in treating problematic methamphetamine use. Led by the

Rangiwaho Marae community with support from an inter-disciplinary

team of researchers and practitioners from around the country, Rua is

responsible for the cultivation and regulatory aspects of the project.

With methamphetamine addiction at an all-time high in our local

communities, this project holds particular importance for us. It has

also created a local employment opportunity, with a former Rua intern

now employed full-time to lead our mushroom cultivation programme

through funding provided by the Tū Wairua project.

The therapeutic use of psilocybin is experiencing significant growth

worldwide, and the Tū Wairua project is at the forefront of this field

both in Aotearoa New Zealand and, to some degree, internationally.

Tū Wairua is the world's first Indigenous-led clinical trial of psilocybin-

containing mushrooms, and one of only three studies globally

examining full-spectrum psilocybin mushrooms as a therapeutic

product. It also marks the first time DNA sequencing has been carried

out on Aotearoa's indigenous psilocybe species.

As interest in Psilocybin-Assisted Therapy continues to grow, so does

the scope of Tū Wairua with another clinical trial funded to research

whether it can help reduce symptoms of mild Traumatic Brain Injury

for sportspeople.

The therapeutic use of

psilocybin is experiencing

significant growth worldwide,

and the Tū Wairua project is

at the forefront of this field.

Te ripoata GHG o Rua mo FY26
Rua’s FY26 GHG report

GHG emissions are a key contributor to climate

change. The New Zealand Government has set a

2050 target of net zero emissions of all GHGs other

than biogenic methane.

The first step in taking impactful climate action is to

understand the amount and type of GHG emissions

a business generates. Informed decisions can then

be made to implement effective reductions.

For this purpose, we measured our emissions

inventory for FY26, and have committed to

managing and reducing our GHGs.

Scope ➀ and ➁ emissions reduced by 20%

Rua's core emissions have reduced 20% year on year

which is a significant improvement as we continue to

streamline operations in New Zealand. The key reason for

this reduction has been the reduction in the use of mobile

fleet and also the improvements in energy efficiency at

the Ruatorea cultivation site.

Scope ➂ emissions reduced by 63%

Scope 3 emission reductions are primarily the result of

more accurate data being received as well as a change in

the mix of higher value products that have been brought

to market.

FY24 was the first year we measured Purchased

Goods and Services and we have continued this for FY26.

We have improved the level of accuracy in FY26 as we use

more recent GHG emissions research data.

During FY27 we will continue to improve unit reporting of

our emissions and also work with suppliers to obtain more

accurate data.

Scope

➀


Direct GHG emissions from sources owned or controlled

by Rua, or emissions released into the atmosphere as

the direct result of the business’s activities.

Scope

➁


Indirect GHG emissions from the generation of

purchased electricity, heat and steam.

Scope

➂


Indirect GHG emissions that occur as a consequence

of Rua’s activities but from sources not owned or

controlled by the business, such as air travel. This

year, Scope 3 emissions include Purchased Goods

and Services.

36

Whai hua mo apopo

Towards sustainability

As a business with a deep sense of

kaitiakitanga, we believe Rua has a

responsibility to protect and nurture

the environment, and share the

benefits of a successful business

with our community.

We have developed a bespoke

Rua Sustainability Framework that

aligns with the United Nations Global

Compact Sustainable Development

Goals. It underpins our dedication

to being an ethical and sustainable

business.

This Framework informs business

strategy, shapes how we engage

with stakeholders, supports

sustainable decision-making

processes and creates value.

Since FY22 we have undertaken

carbon audits to set an underlying

knowledge base from which to

continue to improve.

In FY26, our fifth year of GHG

measuring and reporting, we have

further integrated our reporting

systems and obtained more accurate

data on GHG emissions from

Purchased Goods and Services.

This year has seen a reduction across

all emissions, primarily driven by a

reduction in the use of the mobile fleet

and improvements in energy efficiency

at the Ruatorea cultivation site.

This reporting, alongside our internal

actions, is important for us in our

journey to become a sustainable

business.

Total GHG emissions tCO2-e
Total GHG emissions by scope tCO2-e

Carbon Productivity, $ Revenue per tCO2e

Scope

➀

14231241513332017251942788062040763

Scope

➁

Scope

➂

217

$101

129 2079794847

■ FY22 | ■ FY23 | ■ FY24 | ■ FY25 | ■ FY26

■ FY22 | ■ FY23 | ■ FY24 | ■ FY25 | ■ FY26

■ FY24 | ■ FY25 | ■ FY26

One off refrigerant leak

Purchased Goods and Services

Purchased Goods and ServicesPurchased Goods and Services

Purchased Goods and Services

Purchased Goods and Services

Purchased Goods and Services

$727

$3,536

37Rua Bioscience ― Annual Report 2026

38
Rarangi purongo putea

Index to the consolidated financial statements

Independent Auditor’s Report

Consolidated Statement of Profit or Loss and Other Comprehensive Income

Consolidated Statement of Changes in Equity

Consolidated Statement of Financial Position

Consolidated Statement of Cash Flows

Notes Forming Part of the Consolidated Financial Statements

Shareholder Information

Contact Directory

39

42

43

44

45

46

78

90

OTHER INFORMATION

Nga ripoata putea

Financial statements

39Rua Bioscience ― Annual Report 2026

PricewaterhouseCoopers, PwC Centre, 109 Ward Street, PO Box

191, Hamilton 3240, New Zealand

T: +64 7 838 3838

pwc.co.nz

Independent auditor’s report

To the shareholders of Rua Bioscience Limited

Disclaimer of opinion

We were engaged to audit the consolidated financial statements of Rua Bioscience Limited (the Company),

including its subsidiary (the Group) which comprise:

• the consolidated statement of financial position as at 30 June 2026;

• the consolidated statement of profit or loss and other comprehensive income for the year then ended;

• the consolidated statement of changes in equity for the year then ended;

• the consolidated statement of cash flows for the year then ended; and

• the notes to the financial statements, comprising material accounting policy information and other explanatory

information.

We do not express an opinion on the accompanying consolidated financial statements of the Group. Because of the

significance of the matters described in the ‘Basis for disclaimer of opinion’ section of our report, we have not been

able to obtain sufficient appropriate audit evidence to provide a basis for an audit opinion on these consolidated

financial statements.

Basis for disclaimer of opinion

As described in Note 2(f), the Group incurred a net loss of approximately $3.4m and recorded net cash operating

outflows of approximately $2.96m for the year ended 30 June 2026. The Board and management prepared cash

flow forecasts for the next 12 months. These indicate that, without an additional capital raise, the Group will not

have sufficient cash to meet minimum expenditure commitments and support its current level of activity for at least

12 months from the date the financial statements are authorised.

In addition, the Group has recognised goodwill of $2.19m, property, plant and equipment of $1.74m, right of use

assets of $0.03m and assets in disposal groups held for sale of $0.87m (together, the ‘assets’). As described in note

13, the Directors assessed recoverable amounts of the intangible assets using a value in use model that involves

significant judgement over future revenues and margins and all asset values assume access to sufficient funding to

deliver the plan.

Given the inherent uncertainty in forecasting the Group’s future cash flows and the absence of adequate committed

funding to deliver the forecast, we are unable to obtain sufficient appropriate audit evidence to conclude on the

appropriateness of the going concern basis. We were also unable to obtain sufficient appropriate audit evidence to

support:

• the revenue and margin forecasts in the intangible assets value in use model due to the significance of the

growth assumptions and the early-stage involvement with new customers, and

40Financial statements

2 PwC - Independent auditor’s report

• the fair value assessment of the Gisborne facility due to the limited comparable properties in that market

and the length of time the facility has been marketed for sale without a committed purchase eventuating.

As a result, we were unable to determine whether any adjustments might be necessary to the value of the Group’s

assets in the consolidated statement of financial position, the impairment charge and loss after tax in the

consolidated statement of profit or loss and other comprehensive income, and the related movements in the

consolidated statement of changes in equity.


Independence

We are independent of the Group in accordance with Professional and Ethical Standard 1 International Code of

Ethics for Assurance Practitioners (including International Independence Standards) (New Zealand) issued by

the New Zealand Auditing and Assurance Standards Board (PES 1) and the International Code of Ethics for

Professional Accountants (including International Independence Standards) issued by the International Ethics

Standards Board for Accountants (IESBA Code), as applicable to audits of financial statements of public interest

entities. We have also fulfilled our other ethical responsibilities in accordance with PES 1 and the IESBA Code.

Other than in our capacity as auditor we have no relationship with, or interests in, the Group. Certain partners and

employees of our firm may deal with the Group on normal terms within the ordinary course of trading activities of

the business.


Responsibilities of the Directors for the financial statements

The Directors are responsible, on behalf of the Company, for the preparation and fair presentation of the financial

statements in accordance with NZ IFRS and IFRS Accounting Standards, and for such internal control as the

Directors determine is necessary to enable the preparation of financial statements that are free from material

misstatement, whether due to fraud or error.

In preparing the financial statements, the Directors are responsible for assessing the Group’s ability to continue as a

going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of

accounting unless the Directors either intend to liquidate the Group or to cease operations, or have no realistic

alternative but to do so.

Auditor’s responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements, as a whole, are free from

material misstatement, whether due to fraud or error, and to issue an auditor’s report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with

ISAs (NZ) and ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud

or error and are considered material if, individually or in the aggregate, they could reasonably be expected to

influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located at the External

Reporting Board’s website at:

https://www.xrb.govt.nz/standards/assurance-standards/auditors-responsibilities/audit-report-1-1/

This description forms part of our auditor’s report.

41Rua Bioscience ― Annual Report 2026

3 PwC - Independent auditor’s report

Who we report to

This report is made solely to the Company’s shareholders, as a body. Our audit work has been undertaken so that

we might state those matters which we are required to state to them in an auditor’s report and for no other purpose.

To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the Company

and the Company’s shareholders, as a body, for our audit work, for this report, or for the opinions we have formed.

The engagement partner on the audit resulting in this independent auditor’s report is Matthew White.

For and on behalf of:

PricewaterhouseCoopers Hamilton

22 September 2026

42Financial statements
Consolidated Statement of Profit or Loss

and Other Comprehensive Income

For the year ended 30 June 2026

Note2026

$

2025

$

Revenue from contracts with customers 52,581,5331,511,282

Other income6316,477388,451

Total revenue and other income2,898,0101,899,733

Inventory expense 7(1,760,482)(976,501)

Research and development costs7(877,575)(944,808)

Impairment of assets held for sale25(23,896)(36,260)

Other expenses7(3,310,938)(3,239,970)

Total expenses before operating loss(5,972,891)(5,197,539)

Operating loss before net financing costs(3,074,881)(3,297,806)

Finance income32,1652,247

Finance expense(316,944)(160,103)

Net finance costs4(284,779)(157,856)

Loss before tax (3,359,660)(3,455,662)

Income tax (expense)8--

Loss after tax(3,359,660)(3,455,662)

Other comprehensive income

Items that will or may be reclassified to profit or loss: Exchange

(losses)/gains arising on translation of foreign operations

(66,599)8,929

Other comprehensive (loss)/income for the year, net of tax(66,599)8,929

Total comprehensive loss for the year attributable to

shareholders

(3,426,259)(3,446,733)

Earnings per share for loss attributable to the ordinary

equity holders of the Company

Loss attributable to ordinary equity holders of the Company

Basic ($)10(0.01)(0.02)

Diluted ($)10(0.01)(0.02)

The above statements should be read in conjunction with the accompanying notes.

43Rua Bioscience ― Annual Report 2026
Consolidated Statement of Changes in Equity

For the year ended 30 June 2026

Note

Share

capital

Foreign

currency

translation

reserve

Warrant

reserve

Share

option

reserve

Accumulated

losses

Total

equity

$$$$$$

Opening balance at

1 July 2024

43,952,936(6,296)-333,324(37,513,306)6,766,658

Total comprehensive loss

for the year

- Loss for the year----(3,455,662)(3,455,662)

- Other comprehensive income-8,929---8,929

Total comprehensive loss for the year-8,929--(3,455,662)(3,446,733)

Transactions with owners

- Issue of share capital211,648,229----1,648,229

- Share based payment(147,703)----(147,703)

- Warrants issued18--28,479--28,479

- Share-based payment24---41,782-41,782

- Share options vested and

exercised

21, 24------

Total transactions with owners1,500,526-28,47941,782-1,570,787

Balance at 30 June 202545,453,4622,63328,479375,106(40,968,968)4,890,712

Total comprehensive loss for the year

- Loss for the year----(3,359,660)(3,359,660)

- Other comprehensive income-(66,599)---(66,599)

Total comprehensive loss for the year-(66,599)--(3,359,660)(3,426,259)

Transactions with owners

- Issue of share capital213,016,245----3,016,246

- Costs of issuing share capital(303,668)----(303,669)

- Warrants issued18--69,081--69,081

- Employee share options

expense

24---8,780-8,780

- Share options: exercised

1

;

forfeited

2

21, 24242,200

1

--(383,886)141,686

2

-

Total transactions with owners2,954,777-69,081(375,106)141,6862,790,438

Balance at 30 June 202648,408,239(63,966)97,560-(44,186,942)4,254,891

The above statements should be read in conjunction with the accompanying notes.

44Financial statements
Consolidated Statement of Financial Position

As at 30 June 2026

Note2026

$

2025

$

Current assets

Cash and cash equivalents 4533,698241,421

Trade and other receivables 16524,544366,552

Prepayments17616,270401,740

Inventory 11588,391405,106

Assets in disposal groups held for sale25866,765890,662

Total current assets 3,129,6682,305,481

Non-current assets

Property, plant and equipment 121,742,4072,144,010

Goodwill13, 142,194,9472,194,947

Right-of-use lease assets 1530,85462,167

Other receivables1675,00075,000

Total non-current assets 4,043,2084,476,124

Total assets 7,172,8766,781,605

Current liabilities

Borrowings181,717,467725,307

Trade and other payables 19993,024864,442

Employee benefit liabilities20163,297192,301

Lease liabilities 4, 1513,08040,749

Liabilities in disposal groups held for sale256,25830,155

Total current liabilities 2,893,1271,852,954

Non-current liabilities

Lease liabilities4, 1524,85937, 9 3 9

Total non-current liabilities 24,85937, 9 3 9

Total liabilities2,917,9861,890,893

Net assets 4,254,8914,890,712

Equity

Share capital 2148,408,23945,453,462

Accumulated losses (44,186,942)(40,968,968)

Warrant equity reserve1897,56028,479

Foreign currency translation reserve(63,966)2,633

Share option reserve-375,106

Total equity 4,254,8914,890,712

The consolidated financial statements on pages 42 to 45 were approved and authorised for issue by the

Board of Directors on 22 September 2026 and were signed on its behalf by:

______________________ (Director) ______________________ (Director)

The above statements should be read in conjunction with the accompanying notes.

45Rua Bioscience ― Annual Report 2026
Consolidated Statement of Cash Flows

For the year ended 30 June 2026

Note2026

$

2025

$

Cash flows from operating activities

Receipts from customers2,463,1921,353,961

Grant income received217,600169,876

Sundry income received 26,05097,847

Payments to suppliers and employees(5,668,844)(4,409,123)

Net cash outflows from operating activities9(2,962,002)(2,787,439)

Cash flows from investing activities

Interest income5,8742,247

Proceeds from sale of plant and equipment1,213106,940

Purchase of property, plant and equipment(1,514)(3,431)

Net cash inflows from investing activities5,573105,756

Cash flows from financing activities

Issue of ordinary shares2,819,6781,648,229

Warrants issued69,08128,479

Proceeds received from borrowings2,339,3811,285,631

Repayment of borrowings(1,569,815)(692,667)

Share issue costs paid (303,668)(147,703)

Principal elements of lease payments(43,869)(78,674)

Interest paid(68,060)(27,757)

Net cash inflows from financing activities 3,242,7282,015,538

Net Net increase/(decrease) in cash and cash equivalents286,299(666,145)

Cash and cash equivalents at beginning of year241,421895,131

Exchange gains on cash and cash equivalents5,97812,435

Cash and cash equivalents at end of year4533,698241,421

The above statements should be read in conjunction with the accompanying notes.

46Financial statements
Notes Forming Part of the Consolidated Financial Statements

For the year ended 30 June 2026

1. Reporting entity

The consolidated financial statements comprise the results of Rua Bioscience Limited and its subsidiaries

(together, “the Group”).

Rua Bioscience Limited (“the Company”) is a company incorporated and domiciled in New Zealand and

registered under the Companies Act 1993. The address of the Company’s registered office and principal place

of business is 704 Te Araroa Road, Ruatoria.

The Company is principally engaged in the business of research and development, and pharmaceutical

distribution and marketing.

2. Basis of preparation

(a) Statement of compliance

The consolidated financial statements have been prepared in accordance with New Zealand Generally

Accepted Accounting Practice (NZ GAAP), being in accordance with New Zealand Equivalents to

International Financial Reporting Standards (NZ IFRS) and other New Zealand accounting standards and

authoritative notices that are applicable to entities that apply NZ IFRS and International Financial Reporting

Standards Accounting Standards (IFRS Accounting Standards). They comply with interpretations issued by

the IFRS®Interpretations Committee (IFRS IC) applicable to companies reporting under IFRS® Accounting

Standards.

The Company is listed on the NZX Main Board and is a Financial Markets Conduct (‘FMC’) reporting entity

under Part 7 of the Financial Markets Conduct Act 2013. The consolidated financial statements have also been

prepared in accordance with the requirements of the Companies Act 1993, the Financial Markets Conduct Act

2013 and the Main Board/Debt Market Listing Rules of NZX Limited.

The Group is a Tier 1 for-profit entity for the purposes of complying with NZ GAAP.

These consolidated financial statements include non-GAAP financial measures that are not prepared in

accordance with NZ IFRS. The Group presents Net Tangible Assets, in Note 26. The Group believes that this

non-GAAP measure provides useful information to readers, as this is a required disclosure under the NZX

Listing Rules, but it should not be viewed in isolation, nor considered as a substitute for measures reported in

accordance with NZ IFRS. Non-GAAP measures as reported by the Group may not be comparable to similarly

titled amounts reported by other companies.

The consolidated financial statements are presented in New Zealand dollars ($), which is also the Company’s

functional currency. All financial information presented has been rounded to the nearest dollar.

(b) Material accounting policy information

Material accounting policies have been disclosed alongside the related notes in the consolidated financial

statements.

(c) Basis of measurement

The consolidated financial statements have been prepared on a historical cost basis, except for the items

detailed in note 2(g).

47Rua Bioscience ― Annual Report 2026
(d) New standards, interpretations and amendments

(i) New standards mandatorily effective during the period

There are no new disclosures, standards or interpretations material to the Group to be applied during

the year.

(ii) Issued, but not yet effective

There are a number of standards, amendments to standards, and interpretations which have been issued

that are effective in future accounting periods that the Group has decided not to adopt early.

The following amendments are effective for the periods beginning 1 January 2026 and onwards:

NZ IFRS 18 Presentation and Disclosure of Financial Statements (effective 1 January 2027)

NZ IFRS 18 Presentation and Disclosure in Financial Statements supersedes NZ IAS 1 and will result

in major consequential amendments to NZ IFRS Accounting Standards including NZ IAS 8 Basis of

Preparation of Financial Statements (renamed from Accounting Policies, Changes in Accounting Estimates

and Errors). Even though NZ IFRS 18 will not have any effect on the recognition and measurement of items

in the consolidated financial statements, it is expected to have a significant effect on the presentation and

disclosure of certain items. These changes include categorisation and sub-totals in the statement of profit

or loss, aggregation/disaggregation and labelling of information, and disclosure of management-defined

performance measures.

The Group is currently assessing the impacts of NZ IFRS 18 and at each subsequent reporting period, will

provide an update on the progress towards transition to NZ IFRS 18. The Group expects to adopt its first

NZ IFRS 18 compliant interim financial statements for the period ended 31 December 2027.

Besides the item above, there are no new and amended standards expected to have a material impact on

the Group.

(e) Accounting estimates and judgements made

The preparation of the consolidated financial statements, in conformity with NZ IFRS, requires management

to make judgements, estimates and assumptions that affect the application of accounting policies and the

reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an on-going basis, with revisions to accounting

estimates recognised in the period in which the estimates are revised and in any future periods affected.

Details of significant judgements and estimates made by management in the current period include:

Judgements

− Determination of agent versus principal in respect of the Group’s arrangements with distributors (note 5).

− Recognition (or not) of deferred tax assets related to carried forward tax losses (note 8).

− Recognition of research and development tax credits and research and development expenses (notes 6,

note 7 and note 16).

− Determination of non-current assets held for sale (note 25).

− Preparation of the financial statements on a going concern basis (note 2(f)).

Estimates

− Assessment of impairment for non-financial assets (note 12, note 14 and note 25)

The Group assess the potential climate related risks associated with the location of its facilities and other

key operations in the regions it operates in and considers that there are no material impacts on the current

consolidated financial statements.

2. Basis of preparation (continued)

48Financial statements
2. Basis of preparation (continued)

(f) Going Concern

These consolidated financial statements for the year ended 30 June 2026 have been prepared on the going

concern basis, which assumes that the Group will continue to be able to meet its liabilities as they fall due for a

period of at least 12 months from the date of issuing these consolidated financial statements.

Given the Group’s net operating loss after tax of $3,359,660 (2025: $3,455,662) and net operating cash outflow

of $2,962,002 (2025: $2,787,439) for the year ended 30 June 2026, and in addition to its reduced liquid net asset

position, the Board and management have prepared operating cash flow forecasts for the next 12 months. These

indicated that the Group will not have sufficient cash to meet its minimum expenditure commitments and support

its current levels of activity without undertaking additional action.

The Group’s liquid net assets position has been improved by the receipt of $300,000 under the Group’s

Convertible Note Facility announced on 10 August 2026. The Group remains committed to raising further equity to

meet the business requirements to reach profitability and become self-sustaining.

Accordingly, the Directors are focussed on plans to increase the cash flow of the business and have also evaluated

the following factors in determining that the going concern assumption is appropriate:

(i) Sales and operational improvements: The Group’s operational forecasts include assumptions regarding a

number of opportunities in key markets. As at the date of signing these consolidated financial statements, the

Group has achieved the following:

- Increased sales and market share in Australia year-on-year by partnering with key clinic chains.

- Increased sales and market share in New Zealand year-on-year as well as recently receiving five new

product approvals for the market which will be introduced in the coming months.

- Confirmed a new sales and distribution agreement with one of the United Kingdom’s largest clinic and

distribution chains for the supply and sale of New Zealand sourced medicinal cannabis.

- Established key genetic material in Canada in FY26 with our partners Apollo Green thus creating an

emerging opportunity in one of the world’s largest adult use and medicinal cannabis markets.

- Achieved first sales revenue in the new emerging market of Czechia.

(ii) Debt facility: Management and the Board were successful with the Group’s existing shareholders and secured

additional debt funding to meet operational cashflow requirements. As at 30 June 2026, $1,060,000 had

been provided to the group under this debt facility. Of this amount $756,000 had been received during the

year ended 30 June 2026 and $304,000 had been received in the prior financial year. At the time of this

report $48,000 had been repaid upon maturity and $592,000 had been rolled over for a further year.

(iii)Facility sale: The Group remains committed to finding a buyer for its Gisborne facility which includes the

leasehold buildings held as available for sale in addition to manufacturing and extraction equipment.

The Group continues to expect the sale and settlement of these assets and is actively engaged with

interested parties. Upon settlement, the consideration will firstly be applied to the Group’s loan against

the building, inclusive of accrued contractual interest and additional $100,000 bullet payment, with

the net proceeds amount then being available to the Group.

The Group has also seen a significant increase in operating revenue in the year ended 30 June 2026 giving further

confidence in the Group’s operating model. The Group also forecasts a number of significant operating milestones

over the coming 12 months including:

- Continued expansion of product offerings in Australia, Germany, United Kingdom, Czechia and New

Zealand;

- Secured a significant sales and distribution agreement with a leading clinic chain in the United Kingdom;

and

- Establishment of Rua genetics in several countries including:

o In Canada under license with Apollo Green; and

o Trial crops in New Zealand and Portugal.

These will further the Group’s plans to achieve a sustainable operating model in line with its projections.

49Rua Bioscience ― Annual Report 2026
2. Basis of preparation (continued)

(f) Going Concern (continued)

The Directors believe that the Group will be sufficiently successful in achieving the above, and on this basis, are

of the view that it is appropriate to continue to adopt the going concern assumption in the preparation of these

consolidated financial statements.

Furthermore, the Group’s ability to meet its forecast cash requirements is dependent on a combination of achieving

forecast revenue growth, successfully completing the planned capital raise, managing the repayment or renewal

of existing debt facilities, and completing the facility. There is uncertainty as to whether the capital raise will be

successfully completed and the amount of capital that will ultimately be raised, and there is also uncertainty

regarding the timing and proceeds of any sale of the facility, and the extent to which existing debt facilities may

need to be renewed or refinanced.

The Director's recognise that there are uncertainties regarding achieving revenue forecasts, raising sufficient capital,

managing the repayment or renewal of existing debt facilities, and completing the facility sale on acceptable terms

and within the required timeframe.

These events and conditions identified indicate that material uncertainties exist that may cast significant doubt

on the Group’s ability to continue as a going concern and, therefore, that it may be unable to realise its assets

and discharge its liabilities in the normal course of business.

These consolidated financial statements do not include any adjustments relating to the classification and

recoverability of recorded asset amounts or to the amounts and classification of liabilities that may be necessary

should the Group be unable to continue as a going concern.

(g) Fair value measurement

The fair value of certain assets and liabilities included in the Group’s consolidated financial statements is disclosed.

Determining the fair value of these assets and liabilities utilises market observable inputs and data as far as possible.

For more detailed information in relation to the fair value measurement of the items above, please refer to the

applicable notes.

− Borrowings, disclosure of fair value (note 4)

− Financial assets and liabilities at amortised cost, disclosure of fair value (note 4)

− Measurement of compound financial instruments (note 18)

− Assets in disposal groups held for sale (note 25)

− Impairment of non-financial assets (notes 12 and 25)

(h) Impairment of non-financial assets and Goodwill

The cash-generating unit to which Goodwill is allocated to is tested for impairment at each reporting date and, at

any other time in which there are indicators of impairment (refer to note 13). For an asset that does not generate

largely independent cash inflows, the recoverable amount is determined for the cash-generating unit to which the

asset belongs.

The carrying amounts of the Group’s property, plant and equipment (note 12), intangible assets (note 14) and

right-of-use assets (note 15) are reviewed at each reporting date to determine whether there is any indication of

impairment. If any such indication exists, then the asset’s recoverable amount is estimated.

An impairment loss is recognised whenever the carrying amount of an asset exceeds its recoverable amount (being

the higher of value-in-use and fair value less costs of disposal). Impairment losses directly reduce the carrying

amount of assets and are recognised in profit or loss.

50Financial statements
3. Segment reporting

The Group operates in one segment, its primary business being research and development and the sale of

pharmaceutical products in New Zealand, Australia, and Europe. As the Group remains in early growth phase,

resource allocation decisions are made centrally to ensure capital is managed effectively and efficiently and to

optimise the consolidated financial results of the Group.

The chief operating decision maker has been identified as the Chief Executive Officer (CEO), as they make all

the key strategic resource allocation decisions related to the Group’s segment.

The Group currently derives revenue from customers through the sale of goods in New Zealand, Australia, and

Europe. The Group’s revenues are analysed by geography on the basis of the jurisdiction in which the goods

are sold and have been disaggregated in this way in note 5.


4. Financial instruments and financial risk management

and capital management

This note describes:

(A) The Group’s accounting policies with respect to financial instruments recognised in the Group’s

consolidated financial statements, and detail of those balances.

(B) The nature of the financial risk that the Group is exposed to, and the Group’s objectives, policies and

processes for managing those risks, the methods used to measure them, and sensitivity analysis to

movements in rates (where applicable).

(C) The nature of the Group’s Capital Management policies.

(A) Financial instruments recognised

The Group recognises financial assets and financial liabilities when it becomes party to the contractual

provisions of the financial instrument.

Financial assets

The Group classifies its financial assets depending on the purpose for which the asset was acquired (i.e. the

business model) and the contractual terms of the cash flows.

Amortised cost

These comprise cash and cash equivalents, certain trade and other receivables and term deposit investments.

Cash and cash equivalents comprise of cash on hand and demand deposits, as well as highly liquid deposits

that are readily convertible to known amounts of cash and which are subject to an insignificant risk of

changes in value, with terms of 90 days or less.

These financial assets are:

− Initially measured at fair value, plus directly attributable transaction costs.

− Subsequently measured at amortised cost using the effective interest rate method, less provision for

impairment. Cash and cash equivalents and investments are held with “investment grade” financial

institutions and are deemed to have no significant increase in credit risk in terms of impairment.

− Derecognised when the contractual rights to the cash flows from the financial asset expire or are

transferred.


Financial liabilities

The Group classifies its financial liabilities depending on whether (or not) it meets the definition of a financial

liability at fair value.

51Rua Bioscience ― Annual Report 2026
Categories and fair values of the Group’s financial instruments

Note

Financial assets

at amortised cost

Financial liabilities

at amortised cost

Total

carrying amount

Fair

value

FY26$$$$

Cash and cash equivalents4533,698-533,698(a)

Trade and other receivables16399,460-399,460(a)

Trade payables 19-(807,390)(807,390)(a)

Borrowings18-(1,717,467)(1,717,467)(a)

Lease liabilities15-(44,197)(44,197)(b)

Total933,158(2,569,054)

Financial assets

at amortised cost

Financial liabilities

at amortised cost

Total

carrying amount

Fair

value

FY25$$$$

Cash and cash equivalents4241,421-241,421(a)

Trade and other receivables16289,065-289,065(a)

Trade payables19-(688,412)(688,412)(a)

Borrowings18-(725,307)(725,307)(a)

Lease liabilities15-(78,688)(78,688)(b)

Total530,486(1,492,407)

(a) Due to their short-term nature, the carrying value of these financial instruments approximates their fair value.

(b) Not required to be disclosed per NZ IFRS 7.

4. Financial instruments - risk management (continued)

Other financial liabilities at amortised cost

These include trade and other payables, borrowings and lease liabilities recognised in the consolidated

statement of financial position.

These financial liabilities are:

− Initially measured at fair value, plus directly attributable transaction costs.

− Subsequently measured at amortised cost using the effective interest rate method.

− Derecognised when the contractual obligation to settle the obligation is discharged, cancelled, or expires.

52Financial statements
4. Financial instruments - risk management (continued)

(B) Financial risk management

The Board has overall responsibility for the determination of the Group’s risk management objectives and

policies and, whilst retaining ultimate responsibility for them, it has delegated the authority for designing and

operating processes that ensure the effective implementation of the objectives and policies to the Group's

finance function. The Board receives monthly reports from the Chief Financial Officer through which it

reviews the effectiveness of the processes put in place and the appropriateness of the objectives and policies

it sets. The Group's finance team also review the risk management policies and processes and report their

findings to the Audit, Finance & Risk Committee.

The overall objective of the Board is to set policies that seek to reduce risk as far as possible without unduly

affecting the Group’s competitiveness and flexibility. Further details regarding these policies as they relate to

the specific financial risks that the Group is exposed to are set out below:

Through its operations, the Company is exposed to the following financial risks:

(a) Credit risk

(b) Market risk

i. Interest rate risk, and

ii. Foreign exchange risk

(c) Liquidity risk

(a) Credit risk

Credit risk is the risk of financial loss to the Group if a counterparty to a financial asset fails to meet their

contractual obligations. The Group’s exposure to credit risk is represented by the carrying amount of cash and

cash equivalents, trade and other receivables and investments.

The Group only holds cash and cash equivalents and investments with financial institutions that are

independently determined credit ratings of "A-" or higher.

If wholesale customers are independently rated, these ratings are used. Otherwise, if there is no independent

rating, risk control assesses the credit quality of the customer, taking into account its financial position, past

experience and other factors. Individual risk limits are set based on internal or external ratings in accordance

with limits set by the board. The compliance with credit limits by wholesale customers is regularly monitored

by line management.

The Group has an Audit, Finance & Risk Committee that monitors credit risk as part of its wider duties.

Cash and cash equivalents are presented in the table below:

(a) Moody's, Fitch

(b) Standard & Poor's, Moody's, Fitch

(c) Fitch

Credit ratingCash and cash equivalentsTotal

30 June 2026$$

Kiwibank

(a)

A1, AA419,450419,450

ANZ

(b)

A1, A+, AA-113,690113,690

PayPal

(c)

A-558558

Total533,698533,698

30 June 2025$$

Kiwibank

(a)

A1, AA144,513144,513

ANZ

(b)

AA-, Aa2, AA-96,90896,908

Total241,421241,421

Interest rates on interest bearing cash and cash equivalents range between 1.80% - 2.55%

(2025: 2.55% - 4.80%).

53Rua Bioscience ― Annual Report 2026
4. Financial instruments - risk management (continued)

Cash and cash equivalents above comprise the following:

20262025

$$

Cash on hand533,698241,421

Total cash and cash equivalents533,698241,421

(b) Market risk

Market risk arises from the Group's:

− Use of interest-bearing borrowings (interest rate risk)

− Credit sales and purchases in foreign currencies (foreign currency risk), and

− Prices of key commodity inputs (price risk).

i. Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate

because of changes in market interest rates.

The Group is only exposed to fixed rate interest rates on its interest-bearing liabilities (lease liabilities and

borrowings) and thus interest rate risk is not currently considered a significant risk.

Net Finance costs recognised in profit or loss comprise:

ii. Foreign exchange risk

The Group is exposed to movements in foreign exchange rates through transactions and balances

denominated in foreign currencies. The Group’s exposures to foreign exchange risk are as follows:

− Sales transactions of $1,268,728 (2025: $1,071,562) denominated in foreign currencies, which are mainly

denominated in Australian Dollar and Euro amounts (2025: Australian Dollar and Euro).

− Inventory purchase transactions of $1,801,062 (2025: $896,360) denominated in foreign currencies, which

are mainly denominated in Australian Dollar and Euro amounts (2025: Australian Dollar and Euro).

− Net investments in foreign operations of $(492,725) (2025: $(589,645)).

The Group has an Audit, Finance & Risk Committee that monitors foreign exchange risk as part of its

wider duties.

There are no open forward exchange contracts at the end of the reporting period (2025: nil).

The net foreign exchange gain/(loss) recognised for the year was $87,016 (2025: $(29,086)).

Note20262025

$$

Interest income – financial assets at amortised cost5,8742,247

Gain on loan modification1826,291-

Total finance income32,1652,247

Interest expense – financial liabilities at amortised cost312,708145,916

Interest expense – lease liabilities4,23614,187

Total finance expense316,944160,103

Total net finance costs284,779157,856

54Financial statements
4. Financial instruments - risk management (continued)

ii. Foreign exchange risk (continued)

Sensitivity analysis

The following table presents the Group’s sensitivity from a reasonably possible strengthening or weakening

NZD against foreign currencies, with all other variables held constant.


As at 30 June 2026

Up to 3

months

Between

3 and 12

months

Between

1 and 2

years

Between

2 and 5

years

Over

5 yearsTotal

$$$$$$

Trade payables807,390----807,390

Borrowings (note 18):

- Short-term lending415,297----415,297

- Inventory finance1,082,060----1,082,060

- Distributor Finance202,108----202,148

- Supplier finance 18,005----18,005

Lease liabilities10,08711,25015,00011,250-47,587

Total2,534,94711,25015,00011,250-2,572,447

As at 30 June 2025

$$$$$$

Trade and other payables715,566----715,566

Borrowings (note 18):

- Short-term lending376,122----376,122

- Inventory finance-280,788---280,788

- Distributor finance 68,397----68,397

- Supplier finance ------

Lease liabilities38,99330,26021,33726,250-116,840

Total1,199,078311,04821,33726,250-1,557,713

(c) Liquidity risk

Liquidity risk arises from the Group’s management of working capital. It is the risk that the Group will

encounter difficulty in meeting its financial obligations as they fall due (refer to note 2(f)).

The Group's policy is to ensure that it will always have sufficient cash to allow it to meet its liabilities when

they become due. To achieve this the Group maintains a monthly forecast on its future cash position to ensure

it can meet financial obligations when they fall due.

The Board receives regular financial statements which include statements of financial position, performance,

and cash flow, as well as budget/forecast variance reports, to ensure it holds or will hold cash equivalents to

meet its obligations.

The following table sets out the contractual maturities (representing undiscounted contractual cash-flows) of

financial liabilities:

30 June 202630 June 2025

Equity

$

Profit

$

Equity

$

Profit

$

10% strengthening of the NZD(14,502)(19,335)1,1892,426

10% weakening of the NZD14,50219,355(1,189)(2,426)

55Rua Bioscience ― Annual Report 2026
4. Financial instruments - risk management (continued)

(C) Capital management

The Group’s objectives when managing capital are to safeguard the entity's ability to continue as a going

concern (refer to note 2(f)), so that it can continue to fund activities for the purposes of deriving sustainable

returns to its shareholders and other stakeholders.

The Group’s capital structure consists of Equity of the Group (comprising issued capital and warrant equity).

The Group is not subject to any externally imposed capital requirements. The Board continually reviews the

capital structure of the Group. As part of this review, the Board considers the availability and cost of capital

and the risks associated therein.

5. Revenue from contracts with customers

The Group recognises revenue from the sale of pharmaceutical goods at a point-in-time when control of the

goods has transferred to the customer. This is typically upon physical delivery of the goods to the customer’s

premise. The transaction price is set by the Group and is as per the agreed contracts in place with customers.

Where goods are sold through distributors, judgement is required to assess which party the Group passes

control of the goods such that they are considered the Group’s “customer” for accounting purposes (i.e., the

distributer, or, the end-purchaser).

Consideration is given to which party has the substantive: (i) responsibility to fulfil the promise to provide

goods (including obligations with respect to any returns); (ii) inventory risk over the goods; and, (iii) Rights to

set pricing.

Distributors are considered to be the Group’s agents.

20262025

Performance obligations satisfied at a point-in-time$$

Sale of goods – New Zealand1,295,805439,720

Sale of goods – Australia1,025,174584,648

Sale of goods – Europe260,554486,914

Total Revenue from Contracts with Customers2,581,5331,511,282

56Financial statements
Note20262025

$$

Research and development grant income124,034140,798

Other government grants79,09376,647

Total government grant income203,127217,445

Gain on sale of property, plant and equipment28368,665

Net foreign exchange gains48 7,0 1 6-

Gain on lease modifications-4,493

Other income26,05197,848

Total other income316,477388,451

6. Other income

(i) Government grants

The Group recognises government grants as other income rather than reducing the costs that they are

intended to compensate.

The Group primarily receives government grants from the following entities:

- Inland Revenue Department (IRD), in the form of R&D tax incentive credits;

- Local government grantors; and

- New Zealand Trade and Enterprise (NZTE).

- Ministry of Business Innovation and Employment (MBIE) (in conjunction with Tu Wairua, a locally led

initiative.

R&D tax incentive credits are accounted for as government grant income as opposed to income tax credits

as the benefit is independent of the taxable profit or tax liability where the Group is eligible for a cash refund;

specific conditions exist for the Group, the R&D activities and the expenditure to be eligible for the tax credits;

and the tax credits are not structured as an additional deduction in computing taxable profit.

The Group recognises R&D tax incentive grant income at its fair value where there is a reasonable assurance

at the reporting date that the R&D tax incentive will be received and all attached conditions will be complied

with. The Group expects to receive the tax credit when the return is filed subsequent to the end of the

reporting period.

Typically, grant funding is approved and paid only upon proof of eligible expenditure.

Other grant income received for the year ended 30 June 2026 primarily relate to:

- Assistance in administering the Group’s compassionate access scheme.

- Pilot research projects related to other biotherapeutic medicines in collaboration with other local parties.

There were no conditions unfulfilled at reporting date in respect of other grants received during the year.

Other income streams recognised by the Group include:

57Rua Bioscience ― Annual Report 2026
20262025

Note

$$

Specific expenses included in operating loss

before net financing costs for the year:


Cultivation costs452,928398,931

Extraction and manufacturing35,47323,001

Inventory expense 111,760,482976,501

Impairment expense2523,89636,260

Accommodation and travel29,88238,991

Communications66,625114,668

Depreciation of property, plant and equipment 12396,636338,844

Depreciation of right-of-use lease assets1512,03364,102

Distribution expenses518,605258,386

Direct research and development expenses*18,38910,552

General145,595110,371

Professional services835,1091,075,155

Insurance183,498193,006

Motor vehicle expenses11,97020,924

Charitable expenses29,69544,238

Licenses40,81228,258

Office expenses4,30018,337

Selling and marketing218,070224,416

Employee benefit expense1,184,9281,034,679

Foreign exchange loss-29,085

Capital raising costs3,961158,834

Total expenses5,972,8915,197,539

Included in the above:

Employee benefit expense

- Short term benefits (wages and salaries)954,673971,019

- Defined contribution plan24,90821,878

- Share-based payment expense24205,34741,782

Total employee benefit expense1,184,9281,034,679

Research and development expenses

- Direct costs270,158303,421

- Indirect costs607,417641,387

Total research and development expenses877,575944,808

7. Expenses

* excludes cultivation, extraction and depreciation and other general overheads costs associated with research and development activities.

58Financial statements
7. Expenses (continued)

(i) Research and development

The Group’s research and development operations are not actively in pursuit of commercial licenses and

as such, the Group does not consider itself to be in the development phase. Accordingly, all research and

development costs are expensed as incurred.

(ii) Fees paid to auditors

Fees incurred for services provided by PricewaterhouseCoopers and included within professional services

expenses are as follows:

20262025

$$

Audit of the financial statements

- Audit of the financial statements – 30 June 2026120,750-

- Audit of the financial statements – 30 June 2025386115,000

- Audit of the financial statements – 30 June 2024-20,024

Total fees paid to auditors121,136135,024

8. Income tax

Tax expense/(credit) comprises current and deferred tax.

In determining the amount of current and deferred tax the Group takes into account the impact of uncertain

tax positions and whether additional taxes and interest may be due. The Group believes that its accruals

for tax liabilities are adequate for all open tax years based on its assessment of many factors, including

interpretations of tax law and prior experience. This assessment relies on estimates and assumptions and may

involve a series of judgements about future events. New information may become available that causes the

Group to change its judgement regarding the adequacy of existing tax liabilities; such changes to tax liabilities

will impact tax expense in the period that such a determination is made.

A deferred tax asset is recognised for unused tax losses, tax credits and deductible temporary differences,

to the extent that it is probable that future taxable profits will be available against which they can be utilised.

Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer

probable that the related tax benefit will be realised.

No fees were incurred for services provided by PricewaterhouseCoopers other than the audit of the financial

statements during the year.

59Rua Bioscience ― Annual Report 2026
20262025

$$

Current tax on profits for the year--

Total current tax--

Origination and reversal of temporary differences(74,788)(57,175)

Prior year tax losses not recognised74,78857,1 75

Total deferred tax expense--

Total income tax expense--

(ii) Reconciliation of income tax expense

The reconciliation of income tax expense is presented below:

8. Income tax (continued)

(i) Income tax recognised in profit or loss

The income tax expense/(credit) recognised for the year includes current and deferred tax as

presented below:

20262025

$$

Loss before income tax expense(3,359,660)(3,455,662)

Tax expense/(income) @28%(940,705)(967,585)

Add/(less) reconciling items

- Expenses not deductible for tax purposes37,30180,378

- Non-assessable income(34,730)(39,639)

- Movement in temporary differences now recognised74,788-

- Building depreciation tax legislation changes-137,955

- Tax losses not recognised for deferred tax863,346788,891

Total income tax expense--

(iii) Imputation credits

The Company has $nil imputation credits as at 30 June 2026 (2025: nil).

(iv) Deferred tax

Deferred tax is calculated in full on temporary differences under the liability method using a tax rate of 28%

(2025: 28%).

Significant management judgement has been exercised to determine that future taxable profits for the Group

are beyond a reliable forecast horizon and that no net deferred tax asset should be recognised.

An amount of deferred tax asset of $9,559,999 (2025: $8,604,612) has not been recognised. The

unrecognised deferred tax asset is comprised of tax losses of $9,559,999 (2025: $8,604,612) and other

temporary differences of $nil (2025: nil).

60Financial statements
8. Income tax (continued)

(iv) Deferred tax (continued)

Details of the deferred tax asset and liability amounts recognised in profit or loss are as follows:

Employee

entitle-

ments

Property,

plant and

equip-

mentAccruals

Lease

liabilities

Right-

of-use

assets

Share-

based

payments

– equity

settledInventory

Carried

forward

tax

lossesTotal

$$$$$$$$$

As at 1 July

2024

35,0284,891(1,927)43,055(43,246)7,838- (45,639)-

Amounts recognised

- In profit or

loss

(744)(196,854)14,177(12,579)17,395(7,838)8,322178,121-

At 30 June

2025

34,284(191,963)12,25030,476(25,851)-8,322132,482-

As at 1 July

2025

34,284(191,963)12,25030,476(25,851)-8,322132,482-

Amounts recognised

- In profit or

loss

6,51770,563350(19,853)17,211--(74,788)-

At 30 June

2026

40,801(121,400)12,60010,623(8,640)-8,32257,694-

61Rua Bioscience ― Annual Report 2026
Employee

entitle-

ments

Property,

plant and

equip-

mentAccruals

Lease

liabilities

Right-

of-use

assets

Share-

based

payments

– equity

settledInventory

Carried

forward

tax

lossesTotal

$$$$$$$$$

As at 1 July

2024

35,0284,891(1,927)43,055(43,246)7,838- (45,639)-

Amounts recognised

- In profit or

loss

(744)(196,854)14,177(12,579)17,395(7,838)8,322178,121-

At 30 June

2025

34,284(191,963)12,25030,476(25,851)-8,322132,482-

As at 1 July

2025

34,284(191,963)12,25030,476(25,851)-8,322132,482-

Amounts recognised

- In profit or

loss

6,51770,563350(19,853)17,211--(74,788)-

At 30 June

2026

40,801(121,400)12,60010,623(8,640)-8,32257,694-

9. Notes Supporting Statement of Cash Flows

(i) Reconciliation of net operating cash flows to profit/(loss)

20262025

$$

Net loss for the year (3,359,660)(3,455,662)

Adjustments for non-cash and non-operating activity items:

- Add back: Depreciation – Property, Plant & Equipment396,636338,845

- Add back: Depreciation – RoU lease asset12,03364,110

- Add back: Impairment expense23,89636,262

- Deduct: Gain on sale of Property, Plant & Equipment(283)(68,665)

- Add back: Loss on sale of Property, Plant & Equipment5,551-

- Deduct: Gain from loan modifications(26,291)-

- Deduct: Gain from lease modifications -(4,493)

- Deduct: Unrealised FX gain

(3)

(98,130)-

- Add back: Share-based payment expense205,34741,782

- Add back: Interest expense 316,944160,100

- Deduct: Interest income (5,874)(2,245)

- Add back: Inventory written off 180,62258,234

1,010,451623,930

Movements in working capital:

- (Increase) in other receivables

(1)

(183,719)(52,723)

- (Increase)/decrease in prepayments(200,066)85,518

- (Increase) in inventories(421,154)(105,501)

- Increase in trade and other payables

(2)

221,149189,846

- (Decrease) in employee benefit liabilities(29,003)(3,629)

- (Decrease) in deferred grant income-(69,218)

(612,791)44,293

Net cash outflows from operating activities(2,962,002)(2,787,439)

(1)

Excludes accruals for interest income (investing activity)

(2)

Excludes accruals for interest expense (financing activity), and payables related to property, plant & equipment (investing activity)

(3)

Certain comparative amounts have been reclassified to conform with the presentation adopted in the current period. This has had no impact on previously

reported profit, total comprehensive income, net assets, equity or cash flows.

62Financial statements
9. Notes supporting statement of cash flows (continued)

(ii) Changes in the Group’s liabilities arising from financing activities (cash and non-cash)

30 June 2025NON-CASHNON-CASHNON-CASHCASHCASH

Opening

Loan

modifications

Lease

remeasurements

Interest

accruedDrawdownPaymentClosing

$$$$$$

Lease liabilities147,780-(13,393)11,892-(67,591)78,688

Lease liabilities -

disposal groups held

for sale

5,988-47,1422,295-(25,270)30,155

Borrowings - short

term loans

---126,121250,000-376,121

Borrowings -

inventory finance

---6,222274,567-280,789

Distributor finance

arrangements -

inventory

----542,176(473,780)68,396

Supplier finance

arrangements -

insurance premiums

----218,888(218,888)-

153,768-33,749146,5301,285,631(785,529)834,149

30 June 2026NON-CASHNON-CASHNON-CASHCASHCASH

Opening

Loan

modifications

Lease

remeasurements

Interest

accruedDrawdownPaymentClosing

$$$$$$

Lease liabilities78,688-(20,777)2,787-(22,759)37, 9 3 9

Lease liabilities -

disposal groups held

for sale

30,155--1,449-(25,346)6,258

Borrowings - short

term loans

376,121(26,291)-65,467--415,297

Borrowings -

inventory finance

280,789--234,978687,876(121,586)1,082,057

Distributor finance

arrangements -

inventory

68,396---1,445,566(1,311,854)202,108

Supplier finance

arrangements -

insurance premiums

---12,263205,939(200,197)18,005

834,149(26,291)(20,777)316,9442,339,381(1,681,742)1,761,664

63Rua Bioscience ― Annual Report 2026
10. Earnings per share

Earnings per share (‘EPS’) is based on profit or loss attributable to ordinary shareholders and excludes other

comprehensive income.

In both years, the Group has not adjusted the weighted average number of shares used in diluted EPS to

reflect the impact of outstanding share-options granted, because as the Group is loss-making, the impact of

the outstanding share options granted is “anti-dilutive” (i.e. decreases the loss per share).

Numerator20262025

$$

(Loss) for the year and earnings (basic and diluted EPS) (3,359,660)(3,455,662)

20262025

DenominatorNo. sharesNo. shares

Weighted average number of shares (basic and diluted EPS)290,525,074194,677,774

11. Inventory

Inventories are recognised at the lower of cost and net realisable value. Cost comprises all costs of purchase,

costs of conversion and other costs incurred in bringing the inventories to their present location and

condition. All inventories are held at their net realisable value at reporting date.

Inventories are measured on a first-in-first-out basis to determine the cost of ordinarily interchangeable items.

Amounts recognised in profit or loss

Inventories recognised as an expense during the year amounted to $1,580,088 (2025: $912,306).

The Group reported write-downs of inventory to net realisable value of $180,398 (2025: $64,195) in the

consolidated statement of profit or loss and other comprehensive income.

Security

The Group’s inventory finance borrowings are secured over the Group’s inventory balances (refer note 18).

20262025

$$

Finished goods588,391405,106

Total588,391405,106

12. Property, plant and equipment

Property, plant and equipment are stated at historical cost less any accumulated depreciation and impairment

losses. Costs includes expenditure directly attributable to the acquisition of assets.

Depreciation is recognised over the estimated useful life of the asset based on estimates by management.

Assets' estimated useful life are reassessed annually. The following estimated depreciation rates have been

used:

- Buildings and fitout*: 20% per annum straight line (2025: 20% straight line)

- Cultivation Containers: 10% diminishing value (2025: 10% diminishing value)

- Office Equipment: 13% to 67% diminishing value (2025: 13% to 67% diminishing value)

- Plant and Equipment: 8% to 100% diminishing value (2025: 8% to 100% diminishing value)

- Vehicles: 13% to 40% diminishing value (2025: 13% to 40% diminishing value)


Impairment

There was no impairment to property, plant and equipment for the year ended 30 June 2026 (2025: nil).

* Buildings are depreciated at 20% to reflect the underlying term of the land lease to which they relate.

64Financial statements
12. Property, plant and equipment (continued)

Buildings and

fitout

Cultivation

containers

Office

equipment

Plant and

equipmentVehiclesTotal

Year ended

30 June 2026

$$$$$$

Opening net

book value

1,550,97384,76847,083441,34519,8412,144,010

Additions---1,514-1,514

Depreciation charge(315,286)(8,477)(5,786)(63,095)(3,992)(396,636)

Disposals(5,799)-(682)--(6,481)

Closing net

book value

1,229,88876,29140,615379,76415,8491,742,407

Cost3,410,202159,196122,2901,521,374140,4735,353,535

Accumulated impairment(486,230)--(509,204)-(995,434)

Accumulated depreciation(1,694,084)(82,905)(81,675)(632,406)(124,624)(2,615,694)

Net book

amount

1,229,88876,29140,615379,76415,8491,742,407

Buildings and

fitout

Cultivation

containers

Office

equipment

Plant and

equipmentVehiclesTotal

Year ended

30 June 2025

$$$$$$

Opening net

book value

1,790,75694,18760,793544,0932 7, 8 702,517,699

Additions---3,431-3,431

Depreciation charge(235,049)(9,419)(9,309)(78,369)(6,699)(338,845)

Disposals(4,734)-(4,401)(27,810)(1,330)(38,275)

Closing net

book value

1,550,97384,76847,083441,34519,8412,144,010

Cost3,429,873159,196126,2621,519,860140,4735,375,664

Accumulated impairment(486,230)--(509,204)-(995,434)

Accumulated depreciation(1,392,670)(74,428)(79,179)(569,311)(120,632)(2,236,220)

Net book

amount

1,550,97384,76847,083441,34519,8412,144,010

As at

1 July 2024

Cost3,441,979159,196140,6481,783,739160,4735,686,035

Accumulated impairment(486,230)--(509,204)-(995,434)

Accumulated depreciation(1,164,993)(65,009)(79,855)(730,442)(132,603)(2,172,902)

Net book amount1,790,75694,18760,793544,0932 7, 8 702,517,699

65Rua Bioscience ― Annual Report 2026
13. Goodwill

Any impairment recognised against goodwill is not subsequently reversed in future periods where the

recoverable amount of a CGU increases above its carrying amount.

(i) Impairment testing of goodwill

Goodwill is monitored at a company level, of a single cash-generating-unit (CGU).

The Group tests whether goodwill has suffered any impairment on an annual basis or where there are specific

indicators of impairment in the period. For the year to 30 June 2026, goodwill was tested for impairment as

at 30 June 2026 (2025: 30 June 2025).

The recoverable amount of the CGU has been determined based on its value-in-use (2025: value-in-use ).

Value-in-use calculations require the use of various estimates and judgements. The calculations use cash flow

projections based on financial budgets approved by management covering a five-year period which include

consideration of the following:

• The existing competitive environment in the key markets which the Group currently operates in, including

the Group’s existing and projected market share, and indicators of overall growth in those markets.

• The current life-cycle stage of the medicinal cannabis industry and the continued trajectory towards

maturity.

• The maturation of supply chains in the industry, as well as the Group’s ability to exploit these going

forward.

• The Group’s current loss-making position, reflecting its early commercial phase, and operating cashflow

requirements as well as the steps taken to date to address these.

Cash flows beyond the five-year period are extrapolated using the estimated growth rates stated below.

These growth rates are consistent with forecasts in industry reports specific to the industry in which the

CGU operates:

Assumptions and approach used to determine values30 June 202630 June 2025

Forecasted sales and costs of sales (CAGR*)

This is based on current market share in existing sales channels as well as

industry trends as at the reporting date.

36.57%43.81%

Pre-tax discount rate

Reflects specific risks relating to the relevant activities of the Group.25.83%26.84%

Long-term growth rate

This is the weighted average growth rate used to extrapolate cash flows

beyond the budget period.

2%2%

* Cash flows for the next five-year period are extrapolated using annual estimated growth rates comprising a compound annual growth rate (‘CAGR’). The CAGR

reflects the low base the business is beginning with, growth rates consistent with forecasts in industry reports specific to the industry in which the CGU operates,

the supply agreements the business has in place and the markets in which the business currently has distribution agreements in place or employees in market.

No impairment was recognised as at 30 June 2026 (2025: nil).

If any one of the following changes were made to the above key assumptions, the carrying amount and

recoverable amount would be equal (eliminating headroom of $2,962,917):

The Directors and management have considered and assessed reasonably possible changes for other key

assumptions and have not identified any instances that could cause the carrying amount of the CGU to

exceed its recoverable amount.

Key assumptionSensitivity

Forecasted sales and costs of sales/’CAGR’34.68%

Pre-tax discount rate34.76%

Long-term growth rate (19.19)%

66Financial statements
14. Intangible assets

Intangible assets are stated at historical cost (being their acquisition date fair value if acquired in a business

combination) less any accumulated amortisation and impairment losses.

GoodwillTotal

$$

(i) Cost

At 1 July 2025 10,448,082

10,448,082

At 30 June 2026 10,448,08210,448,082

At 1 July 202410,448,08210,448,082

At 30 June 2025 10,448,08210,448,082

(ii) Accumulated amortisation and impairment

At 1 July 2025(8,253,135)(8,253,135)

Amortisation charge--

Impairment charge--

At 30 June 2026(8,253,135)(8,253,135)

At 1 July 2024(8,253,135)(8,253,135)

Amortisation charge--

Impairment charge--

At 30 June 2025(8,253,135)(8,253,135)

(iii) Net book value

At 1 July 20242,194,9472,194,947

At 30 June 20252,194,9472,194,947

At 30 June 20262,194,9472,194,947


Impairment

There was no impairment to intangible assets for the year ended 30 June 2026 (2025: nil).

67Rua Bioscience ― Annual Report 2026
15. Leases

All leases are accounted for by recognising a right-of-use asset and a lease liability except for:

− Leases of low value assets; and

− Leases with a duration of 12 months or less.

Initial measurement

Lease liabilities are measured at the present value of the contractual payments due to the lessor over the

lease term, with the discount rate determined by reference to the rate inherent in the lease unless (as is

typically the case) this is not readily determinable, in which case the Group’s incremental borrowing rate on

commencement of the lease is used. Variable lease payments are only included in the measurement of the

lease liability if they depend on an index or rate, however in such cases the initial present value determination

assumes that the variable element will remain unchanged throughout the lease term.

Other variable lease payments are expensed in the period to which they relate.

Right-of-use assets are initially measured at the amount of the lease liability, reduced for any lease incentives

received, and increased for:

− lease payments made at or before commencement of the lease;

− initial direct costs incurred; and

− the amount of any provision recognised where the Group is contractually required to dismantle, remove or

restore the leased asset (typically make-good provisions on buildings)

Right-of-use assets are depreciated on a straight-line basis over the remaining term of the lease or over the

remaining economic life of the asset if, rarely, this is judged to be shorter than the lease term. Right-of-use

assets are also subject to impairment assessment at reporting date.

(i) Information regarding the Group’s leases and leasing activity

The Group leases a number of properties including land, buildings, including commercial office premises, in

the jurisdiction from which it operates.

As standard industry practice, one of the Group’s property leases are subject to periodic CPI increases and/or

market rent reviews. A 1% increase in these payments would result in an additional $253 cash outflow (2025:

$253) compared to the current period’s cash outflow.

The Group’s property leases typically include renewal and termination options. The Group must assess

whether it reasonably expects (or not) to exercise these when determining the lease term.

The Group has one property lease (2025: two leases) where the Group has assessed it does not reasonably

expect to exercise all available renewal options, resulting in a potential additional lease term of 10-20 years

(2025: 10 - 20 years) and potential future lease payments of $150,000 - $300,000 (2025: $150,000 -

$300,000) that are not currently included in measurement of the lease liability recognised for these leases.

68Financial statements
15. Leases (continued)

(ii) Lease related balances as at period end, and amounts for the period

Note20262025

Expenses and income in the period$$

Depreciation

- Leases of property (land and buildings)12,03362,204

Interest expense4,23614,187

Statement of financial position and statement of cash flows

Carrying amount of right-of-use asset

- Leases of property (land and buildings)30,85462,167

Total Lease liabilities9(ii)37, 9 3 9108,843

(Early termination adjustments)/Additions to

Right-of-use assets

(44,674)38,242

Total cash outflow related to leases48,10592,860

69Rua Bioscience ― Annual Report 2026
16. Trade and other receivables

20262025

Note$$

Financial assets classified as amortised cost – current

Trade receivables

324,460214,065

Less: provision for impairment of trade receivables

--

Trade receivables – net

324,460214,065

Financial assets classified as amortised cost –

non-current

Non-trade receivables – NZX Bond75,00075,000

Financial assets classified as amortised cost - total4399,460289,065

GST receivable72,83610,766

Government grants receivable

- Research and development tax credit127,248141,721

Other receivables200,084152,487

Total trade and other receivables599,544441,552

The Group applies the NZ IFRS 9 simplified approach to measuring expected credit losses using a lifetime

expected credit loss provision for trade receivables. This is based on a provision matrix which measures

expected credit loss on a collective basis where trade receivables are grouped based on similar credit risk and

rating.

The expected loss rates are based on the Group’s historical credit losses. The historical loss rates are then

adjusted for current and forward-looking information on macroeconomic factors affecting the Group’s

customers. At reporting date, none of the Group’s trade receivables were past 30 days due.

70Financial statements
17. Prepayments

20262025

$$

Prepaid inventory523,496340,695

Other prepayments92,77461,045

Total prepayments616,270401,740

20262025

$$

Inventory finance borrowings (incl. warrants).1,082,057280,788

Short-term lending 415,297376,122

Distributor finance arrangements - inventory202,10868,397

Supplier finance arrangements – insurance premiums18,005-

1,717,467725,307

Prepayments for future goods or services are recognised in the consolidated statement of profit or loss and

comprehensive income when the Group obtains control of the associated good or service.

Prepayments for inventories are derecognised in the consolidated statement of financial position when the

Group obtains control of the associated inventory items

18. Borrowings

Inventory finance borrowings

During the year, the Group entered into a number of lending arrangements to assist in managing working

capital cash flows. The loans have a 12-month maturity and accrue interest on a monthly basis. The loans are

secured over the Group’s inventory holdings (refer note 11).

As part of the arrangement, lenders were also issued a number of additional warrants for which give the

holders the right to purchase ordinary shares at a fixed price 12 months after the draw-down date. The

warrants expire 3 years after they become exercisable.

As the warrants give the holder the option to purchase a fixed amount of shares for a fixed amount of cash,

they satisfy the ‘fixed-for-fixed’ criterion and, therefore, are classified as equity instruments.

The loans, with their attached warrants, comprise a compound financial instrument and thus, each component

of the instrument has been measured at inception as follows:

- Financial liability: The loan component has been measured at its fair value using a market interest rate

for an equivalent instrument without the attached warrants. The market interest rate applied was

25%. The loan is subsequently measured as a financial liability at amortised cost.

- Equity: The warrants have been valued on a residual basis and are recognised within equity, within the

Warrant equity reserve (refer to note 21). In the current period, $69,081 (2025: $28,479) warrants were

issued in association with compound financial instruments issued.

Short-term lending

During the year, the Group renegotiated its existing short-term lending which was previously due to mature as

at 30 June 2025.

The renegotiations resulted in:

- A new maturity date of 30 June 2026;

- An option to convert the loan into a variable number of ordinary shares of the company provided to the

lender (‘conversion feature’), with the exercise price based on the 20-day volume-weighted-average-price

(‘VWAP’) prior to exercise.

The renegotiations were accounted for as a substantial modification requiring the derecognition of the carrying

value of the original loan, and recognition of the new renegotiated loan at its fair value - resulting in a gain of

$26,291, recognised within Finance income (refer note 4) in the consolidated statement of profit or loss.

71Rua Bioscience ― Annual Report 2026
20262025

Note$$

Trade payables4807,390688,412

Audit fee accrual82,416115,000

Other payables101,32551,244

GST payable1,8939,786

Total trade and other payables993,024864,442

19. Trade and other payables

18. Borrowings (continued)

- Insurance premiums

The Group also enters into supplier finance arrangements to provide the Group with extended payment

terms for insurance costs where the supplier has been paid upfront in full by the financer. Supplier finance

arrangements for insurance premiums are payable over 12 months in monthly instalments.

Distributor and Supplier finance arrangements

- Inventory

The Group has a distributor finance arrangement with certain distributors in New Zealand whereby

distributors provide cash advances to the Group to finance the Group’s purchase of finished goods inventories

which will be sold via the distributors, who are agents of the Group. Cash advances from distributors are

repayable when the finished goods purchased are sold or expire. Otherwise, the Group does not provide any

collateral or guarantees to the distributor.

The conversion feature of the new renegotiated loan represents an embedded derivative at fair value through

profit and loss. Management have determined that the fair value of the conversion feature upon modification

of the loan, and at reporting date, was immaterial.

The existing terms of the loan, which are as follows, remain unchanged:


The loan becomes payable earlier than the contractual maturity date should certain funding

events occur:

(i) In the event that the Group successfully raises a minimum amount of additional share capital.

(ii) Sale of the Group’s manufacturing facility (refer note 25), within certain timeframes.

(iii) Is subject to an additional bullet payment of $100,000 based on the timeframes in which the above

events occur. The inclusion of this amount has been factored into the interest expense accrued onto

the loan under the effective interest method.

The loan is secured by a general security agreement over the assets of the Group.


Subsequent to reporting date, the Group has renegotiated the terms of this loan, agreeing to extend the

maturity date to 30 June 2027.

72Financial statements
21. Share Capital and Reserves

At 30 June 2026, share capital comprised 339,441,705 authorised and issued ordinary shares (2025:

223,648,012). All issued shares are fully paid and have no par value. The holders of ordinary shares are entitled

to receive dividends as declared from time to time and are entitled to one vote per share at meetings of the

Group, and rank equally with regard to the Group’s residual assets. Dividends are unlikely to be declared

whilst the Group is in the growth phase.

Reserves

Exchange differences arising on the retranslation of the foreign operation are accumulated in the foreign

currency translation reserve.

Share-based payments (refer to note 24) are recognised as an expense, with a corresponding increase in

equity (share-based payment reserve), over the vesting period of the awards.

Proceeds on the issue of warrants meeting the definition of equity are recognised in the warrant equity

reserve (refer to note 18).

Relevant details in respect of Warrants issued are outlined as follows:

Warrants are exercisable from the exercise date for a period of 3 years. Exercised and paid for warrants allow

the warrant holder to subscribe for ordinary shares on a 1-for-1 basis.

20262025

No. sharesNo. shares

Opening shares223,648,012159,750,579

Shares issued*

’

**115,793,69363,897,433

Total share capital 339,441,705223,648,012

* During the year ended 30 June 2026:

- 16,799,999 ordinary shares were issued between August and September 2025 to fund short-term working capital;

- 4,966,537 ordinary shares were issued as a share-based payment to reward the Group’s staff for past performance and incentivise future performance.

- 1,400,000 vested share options were exercised by the CEO in accordance with an existing share-based payment scheme.

- 92,627,157 ordinary shares were issued on 18 December 2025 as part of a pro-rata 1-for-3 renounceable rights offer and placement of oversubscription.


** During the year ended 30 June 2025

- 3,968,254 ordinary shares were issued on 20 September 2024 as bridging capital prior to the Group’s capital raise;

- 47,119,179 ordinary shares were issued on 6 December 2024 as part of the Group’s capital raise in the period;

- 12,810,000 ordinary shares were issued as part of the pro-rata rights offer following the Group’s capital raise;

FY26 IssueFY25 Issue

Number of warrants outstanding4,226,9471,699,725

Exercise price$0.015$0.015

Exercise dateAugust – September 2027May – June 2026

Expiry dateAugust – September 2030May – June 2029

20. Employee benefit liabilities

20262025

$$

Short term employee benefits payable

- Wages and salaries6,59651,683

- Accrual for annual and sick leave 151,185135,202

157,781186,885

Defined contribution plan (‘Kiwisaver’) payable5,5165,416

Total employee benefit liabilities163,297192,301

73Rua Bioscience ― Annual Report 2026
22. Related party transactions

(i) Company information

The Group has no parent or ultimate parent entity. There are no individual shareholders holding more than

20% of the ordinary shares of the Group at reporting date.

(ii) Transactions and balances with related parties

During the year the Group entered into the below transactions with entities related to key management

personnel.

Nature of

transactions

Sale/

(purchase)

amount

Interest

expense

Amounts

receivable

(payable)

$$$

30 June 2026

Zenoch Management LimitedPurchases***(49,500)--

Teresa CiprianLoan-5,352(59,439)

Tony BarclayLoan*18,0002,315(19,611)

30 June 2025

Zenoch Management LimitedPurchases***(49,500)--

Teresa CiprianLoan**54,000-(50,129)

(iii) Key Management personnel compensation

Compensation of key management personnel (being those persons having authority and responsibility for

planning, directing and controlling the activities of the Group, including the Directors) was as follows:

Note20262025

$$

Directors fees234,709234,000

Short-term employee benefits264,964257,432

Defined contribution plan payments5,3797,654

Share-based payment expense2471,78041,782

Total key management personnel compensation 576,832540,868

Key management personnel compensation payable3,0854,744

*Included within the initial $18,000 advanced was $1,653 attributable to warrant equity (refer note 18).

**Included within the initial $54,000 advanced was $4,362 attributable to warrant equity (refer note 18).

***Zenoch Management Limited is a Company owned by Teresa Ciprian. Purchases relate to payment of Teresa’s directorship fees.

Inventory finance loans

Loans payable to Directors relate to inventory finance borrowings advanced by the Directors as outlined

above (refer to note 18). Loans advanced by Directors are under the same terms and conditions as all other

lenders under facility.

74Financial statements
Research and Development (R&D) Loss Tax Credit repayment

The Company claimed R&D Loss Tax Credits in the 2019 and 2020 income years under the Income Tax Act

2007. Under the Act, these credits become repayable in certain circumstances where shareholder continuity

thresholds are breached. Following the Company's NZX listing, subsequent dilution of the shareholder base

meant that the Company exceeded the shareholder continuity threshold. The Company obtained tax advice

and lodged a disclosure with Inland Revenue (IRD) setting out its position that, under the specific provisions

of the Act, no repayment was required.

In May 2026, the IRD advised that it had not accepted the Company's position. The Company, based on

advice, does not agree with that determination and is continuing to communicate with the IRD about the

determination.

Having previously assessed a repayment as remote, the Company now considers it possible (but not

probable) and has accordingly disclosed the matter as a contingent liability.

Should the IRD’s alternative interpretation ultimately be upheld, the Company estimates the potential R&D

cash repayment tax exposure at up to $561,243 being the R&D claims for the 2019 and 2020 income years.

Use-of-money interest may also apply to any repayment tax ultimately assessed as payable, however at this

stage this cannot be reliably estimated.

23. Contingent liabilities

75Rua Bioscience ― Annual Report 2026
2026

Number

2025

Number

Outstanding At 1 July 309,023775,874

- Options issued--

- Options vested(309,023)(466,851)

- Options forfeited--

Unvested at 30 June -309,023

Exercisable at 1 July1,090,977624,126

- Options vested(309,023)466,851

- Options exercised1,400,000-

Exercisable at 30 June-1,090,977

24. Share-based payments

(i) Key features and balances of ESOPs

The Group grants options to certain employees under a number of employee share option schemes which are

classified and accounted for as equity-settled share-based payments.

As at 30 June 2026, all of the Group’s outstanding ESOP arrangements had either fully vested (and were

subsequently exercised in full), lapsed or expired.

(ii) Other share-based payment arrangements

During the period ended 30 June 2026, the Group awarded additional non-cash bonuses to employees in the

form of shares for no consideration. The awards were measured at their fair value, being the share price at the

grant date and were recognised immediately as part of employee benefits expenses.

76Financial statements
25. Assets held for sale

Non-current assets are classified as held for sale when their sale is highly probable within 12 months of

meeting the criteria for that classification. Following the classification as held for sale, non-current assets are

not depreciated.

Although the asset has been marketed for sale for a period greater than 12 months, Management and the

Board believes that the facility will be sold and are in ongoing sales dialogue with prospective buyers.

Accordingly, the Group continues to present its manufacturing facility as available for sale.

The following assets and liabilities were held for sale as at 30 June 2026:

Assets classified as held for sale during the period ended 30 June 2026 were measured at the lower of their

carrying value and fair value less costs to sell. The fair value of the building and right-of-use asset associated

with the lease of the land upon which the building sits was derived using the sales comparison approach.

The key input under this approach was the recent observable selling prices for assets of similar nature,

adjusted for condition and location.

30 June 202630 June 2025

Assets classified as held for sale

Property, plant and equipment860,507860,507

Right-of-use assets6,25830,155

Total assets held for sale866,765890,662

Liabilities classified as held for sale

Lease liabilities(6,258)(30,155)

Total liabilities classified as held for sale(6,258)(30,155)

Total net assets held for sale860,507860,507

77Rua Bioscience ― Annual Report 2026
26. Events after the reporting date

Subsequent to reporting date, the Group:

- has confirmed a new sales and distribution agreement in the United Kingdom with one of the world’s

largest medicinal cannabis businesses. The business’s United Kingdom operation is one of the largest

clinic and distribution chains in that market and this marks a significant expansion of Rua's international

commercial footprint through the supply of New Zealand-grown medical cannabis flower into the United

Kingdom market;

- has approved a convertible note facility offered to wholesale lenders for the purchase of inventory to

accelerate sales growth. This facility provides for up to a maximum of $600,000 in additional capital for

the purchase of inventory to support sales growth. To date $300,000 has been received and an additional

$150,000 has been committed under this facility.

- has rolled over and extended $592,000 of its existing debt facility with respective lenders. A further

$48,000 has been repaid on contractual maturity. The Group is in ongoing discussions with the remaining

lenders where the facilities have matured subsequent to reporting date; and

- has negotiated to extend other short-term lending arrangements.

There were no other events subsequent to reporting date that would materially affect these consolidated

financial statements.

27. Subsidiaries

The principal subsidiaries of Rua Bioscience Limited, which have been included in these consolidated financial

statements, are as follows:

Name

Country of

incorporation

and principal

place of business

Proportion of

ownership interest

at 30 June

Non-controlling

interests ownership/

voting interest

at 30 June

202620252026 2025

Rua Bioscience Australia Pty Ltd Australia100%100%--

28. Net tangible assets

Net tangible assets per share is a non-GAAP measure that is required to be disclosed by the NZX Listing

Rules. The calculation of the Group's net tangible assets per share and its reconciliation to the consolidated

balance sheet is presented below:

20262025

$$

Total assets7,172,8766,781,605

(less): Intangible assets(2,194,947)(2,194,947)

(less): Total liabilities(2,917,985)(1,890,893)

Net tangible assets2,059,9442,695,765

Number of shares issued at balance date 339,441,705223,648,012

Net tangible assets per share0.010.01

The subsidiary of the Group has a 30 June reporting date.

78
Nga Korero mo nga

kaipupuri hea

Shareholder information

79Rua Bioscience ― Annual Report 2026

80Shareholder information8080
RangeTotal HoldersShareholding% Shares

1 - 499340104,5180.03

500 - 999193142,5000.04

1,000 - 1,999303391,8980.12

2,000 - 4,9996442,062,6330.61

5,000 - 9,9993562,465,3320.73

10,000 - 49,99970614,822,6484.37

50,000 - 99,9991208,023,3462.36

100,000 - 499,99912225,167,4277. 41

500,000 - 999,9992215,734,3524.64

1,000,000 Over41270,527,05179.70

Total2,847339,441,705100.00


Shareholder Information

Spread of Shareholders

As at 31 July 2026

Rua’s Statement of Corporate Governance as at 21 September 2026 can be found

here: www.ruabio.com/investors

81Rua Bioscience ― Annual Report 20268181
Name

Shareholding% Shares

NEW ZEALAND DEPOSITORY NOMINEE LIMITED <A/C 1 CASH

ACCOUNT>

66,731,27319.66

FNZ CUSTODIANS LIMITED <DTA NON RESIDENT A/C>26,783,0397. 8 9

FANG GROUP INVESTMENT LIMITED23,584,9396.95

GOUGH INVESTMENT CAPITAL LIMITED17,383,3445.12

ACCIDENT COMPENSATION CORPORATION - NZCSD <ACCI40>16,174,7144.77

GREG ANTONY ANDERSON & NICOLA MARIE ANDERSON <THE

ORANGE A/C>

14,876,7934.38

YUN JIANG12,638,9783.72

HIKURANGI ENTERPRISES LIMITED (IN LIQUIDATION)10,532,6203.10

BEVERLEY IDA EVANS5,000,0001.47

RIDINGS BROTHERS LIMITED4,492,1961.32

BREAKAWAY INVESTMENTS LIMITED4,346,4481.28

LUKE RICHARD DIXON & SARAH LYNN DIXON & SEAN ROBERT DIXON

& IAN ARCHIBALD HURST <LUKE & SARAH DIXON FAMILY A/C>

3,869,4931.14

DANTONG GU3,860,6331.14

MARTIN WALTER SMITH & ANETA LISA BIRD & SARA MAREE LUNAM

<WAKAROMA A/C>

3,820,7061.13

FORSYTH BARR CUSTODIANS LIMITED <1-CUSTODY>3,758,9981.11

SIMON SY LUO3,729,0771.10

MICHAEL JOHN WILDING3,650,8461.08

CUSTODIAL SERVICES LIMITED <A/C 4>3,474,2261.02

MARK CARRODUS3,333,3330.98

PRAKASH PANDEY3,333,3330.98

Top 20 holders of ORDINARY SHARES total235,374,98969.34

Total remaining holders balance104,066,71630.66


Top 20 Shareholders

The names and holdings of the 20 largest registered shareholders in Rua as at 31 July 2026 were:

82Shareholder information82
Substantial Product Holders

According to notices given under the Financial Markets Conduct Act 2013, the following were substantial

product holders of Rua as at 30 June 2026. The total number of voting securities (fully paid ordinary shares)

of Rua as at 30 June 2026 was 339,441,705.

Directors’ Shareholdings Interests

As at 30 June 2026 the Directors of the Company had the following relevant interests in Rua’s shares.

Directors’ Share Dealings

In accordance with the Companies Act 1993 between 1 July 2025 and 30 June 2026 the Board received the

following disclosures from Directors of acquisitions and dispositions of relevant interests in shares issued by

the Company and details of such dealings were entered in the Company’s interests register.

NameShareholdingWarrants

Anna Stove1,538,528nil

Panapa Ehau473,498nil

Tony Barclay2,939,376100,642

Teresa Ciprian875,000301,925

DirectorTransactionNumber of securitiesPrice per securityDate

Tony BarclayAllocation of warrants100,642 $0.015 15 August 2025

Tony BarclayPurchase of Shares400,000 $0.03 15 August 2025

Tony BarclayPurchase of Shares800,000 $0.025 18 December 2025

Teresa CiprianPurchase of Shares350,000 $0.025 18 December 2025

Anna StovePurchase of Shares774,632$0.02518 December 2025

NameShareholdings

MR JUN CHU26,748,214

FANG GROUP INVESTMENT LIMITED23,584,939

GOUGH INVESTMENT CAPITAL LIMITED17,383,344

83Rua Bioscience ― Annual Report 202683
Directors' Interests

The following are details of general disclosures of interest by Directors holding office as at 30 June 2026,

pursuant to section 140(2) of the Companies Act 1993. The Director will be regarded as interested in all

transactions between Rua and the disclosed entities.

Current DirectorsCompanyPosition

Anna StovePacific Edge LimitedDirector and Shareholder

Progressive FarmsDirector and Shareholder

Panapa EhauHikurangi Huataukina TrustTrustee

He Toutou mo te Ahika Trust Trustee

Te Papatipu O Uepohatu Charitable Trust Trustee

Teresa CiprianLeaderbrandDirector

Aspeq LtdDirector

Goodfood Group LtdDirector

Superthriller Jetsprint LtdDirector and Shareholder

The Elk CollectiveDirector

Garden to Table TrustTrustee

Zenoch Management LimitedDirector and Shareholder

Tony BarclayBaymatob Pty LtdChair and Shareholder

Pacific Edge LimitedDirector and Shareholder

84Shareholder information84
Independent Directors

In order for a Director to be independent, the Board has determined that they must not be an employee of

Rua or any of its subsidiaries and must have no disqualifying relationships. Independence is determined by the

Board, in accordance with the independence requirements of the NZX Listing Rules and having regard to the

factors described in the Code. Director independence is monitored by the Board on an ongoing basis.

NZX Listing Rules require that there must at all times be at least three Directors of whom two are ordinarily

resident in New Zealand and at least two are independent Directors.

Rua has four Directors of whom three were considered to be independent as at 30 June 2026. Those three

are: the Chair, Anna Stove; Teresa Ciprian and Tony Barclay. Panapa Ehau is a Director, employee and co-

founder of Rua.

In addition, the Directors of Rua's Australian subsidiary company, Rua Bioscience Australia Pty Ltd, are,

Paul Naske and Dean Steer.

Board and Officer Gender Composition

The gender composition of Directors and the Officers as at 30 June 2026 was as follows:

F 30 June 2026 30 June 2025

PositionFemaleMaleGender

Diverse

FemaleMaleGender

Diverse

Director220220

Officers*65053 0

* An officer is a person who is concerned or takes part in the management of Rua’s business and who reports directly to the

Board or the Chief Executive Officer.

85Rua Bioscience ― Annual Report 202685
Evaluation of Performance Against Diversity Policy

Rua’s approach to diversity is outlined in its Diversity and Inclusion Policy, which is available on Rua’s website.

Key areas of focus are:

• Attracting, selecting and retaining qualified and diverse applicants and aiming to have a focus on ethnic

and gender diversity.

• Remunerating and rewarding in an equitable manner on the basis of skill, knowledge and merit.

• Maintaining a workplace that is accommodating of diverse and changing life situations and enables

employees to manage their work and lives through flexible working arrangements.

• Striving for a diverse representation of different groups in society across all levels of Rua’s business and

based on Rua’s origins and values (see the Code of Ethics for a description of Rua’s values).

The Board recognises the critical nature of diversity and inclusion and has ensured this is a key consideration

when making the skill-based appointments required to ensure robust governance as Rua transitions from

start-up to commercialisation. The Board has reviewed Rua’s diversity profile and considers that, at this time,

there is good diversity on the factors that are most relevant to Rua and its employees:

• Understanding and adoption of a bi-cultural working environment is deeply embodied within Rua’s culture.

All recent company publications include content in English and Maori.

• The make-up of the Board is sufficiently diverse for the purposes of forming a strong team, providing

specialised knowledge and expertise in relevant markets, and driving strong business performance.

• Of the 13 employees, 6 are female and 7 are male.


The Board has set a gender diversity objective for the Board of 40% men, 40% women and 20% of

any gender. The Company currently meets this objective.


Meeting Attendance

Board

Audit, Finance

and Risk

Management

Remuneration and

Nominations

Financial Review

Meeting

Current DirectorsAttendedAttendedAttendedAttended

Tony Barclay8 of 96 of 62 of 317 of 19

Teresa Ciprian9 of 96 of 63 of 316 of 19

Panapa Ehau8 of 9N /AN /A17 of 19

Anna Stove9 of 96 of 63 of 318 of 19

86Shareholder information
In addition to his Director's fee, Panapa Ehau also receives a salary as an employee of Rua. In FY26, his salary

was $46,791 and Director's Fee was $45,000 for a total remuneration of $91,791. There was no STI or LTI paid

to Panapa in FY26.

Directors’ Remuneration

Director remuneration is made up of an annual base fee, an additional Chair fee (if applicable) and some

Directors are participants in Rua’s share option plan.

A director fee pool of $324,000 per annum has been approved by shareholders. Any increase to that pool

requires shareholder approval. The base fee for the Chair is $90,000 and for a Director is $45,000. Committee

Chairs are paid a fee for the additional work the role requires.

Members of Committees are not paid an additional fee. The full Director fee pool was not used.

Remuneration Philosophy

Rua's remuneration philosophy is to provide fair, competitive and appropriate remuneration that attracts and

retains the capability needed to deliver the Company's strategy and create sustainable long-term shareholder

value.

Executive remuneration balances fixed remuneration with performance-related reward linked to Board-

approved financial, strategic and operational objectives. In assessing performance, the Board considers both

what has been achieved and how it has been delivered. It retains discretion to ensure remuneration outcomes

reflect company and individual performance, affordability and shareholder interests.

The Board, supported by the Remuneration and Nominations Committee, oversees remuneration and

periodically reviews the framework against Rua's circumstances and relevant market practice. Rua is

committed to fair and equitable remuneration across the organisation and considers diversity as part of its

remuneration oversight, with appropriate disclosures provided to shareholders. Given Rua's small workforce,

percentage-based diversity measures can be significantly influenced by changes involving a small number of

employees and should be considered in that context.

Current DirectorsPositionDirectors' feesCommittee feesTotal

Tony BarclayChair - ARC$45,000$4,500$49,500

Teresa CiprianChair - Rems$45,000$4,500$49,500

Panapa Ehau$45,000$45,000

Anna StoveChair - Board$90,000$90,000

87Rua Bioscience ― Annual Report 2026
Remuneration rangeEmployees

100,000-110,0000

110,001-120,0001

120,001-130,0000

130,001-140,0000

140,001-150,0001

150,001-160,0001

160,001-170,0000

170,001-180,0000

180,001-190,0001

190,001-200,0000

200,001-210,0000

210,001-220,0000

230,001-240,0000

240,001-250,0001

320,001-330,0001

Employee Remuneration

The number of employees of Rua (not being Directors) who received remuneration and other benefits in their

capacity as employees during the year ended 30 June 2026 that exceeded $100,000 per annum is set out in

the table below.

The table below includes the value of equity settled ESOP shares.

Total remuneration

FY26 $321,183

FY25 $220,921

FY24 $232,693

* Salary and Fees includes KiwiSaver and Employer Superannuation Contribution Tax (ESCT).

** ESOP included a 3-year retention agreement (valued at $39,200) and annual performance incentive (valued at $63,000).

CEO Remuneration

For the financial year ended 30 June 2026, the CEO received a total remuneration of $321,183. The CEO is a

participant in the Employee Share Options Programme.

Three-year summary

Cash

(Salary and fees)*

Non-Cash

Equity (ESOP)**

Total

remuneration

FY26 $218,983 $102,200 $321,183

Donations


The following donations were made by Rua and its subsidiaries in the year to 30 June 2026.

Compassionate Access Programme$29,435

Koha$261

Total$29,696

88Shareholder information
Auditor Fees

Fees paid to the auditors include payments to PricewaterhouseCoopers for the following:


There were no other fees payable by the company for other services provided by that firm for FY26.

Dividend Policy

The payment of dividends is not guaranteed, will be at the discretion of the Board, and dependent on a

number of factors.

These factors include the general business environment, operating results and the financial condition of Rua,

future funding requirements, any contractual, legal or regulatory restrictions on the payment of dividends by

Rua and any other factors the Board may consider relevant.

20262025

Audit and review of the financial statements

- Audit of the financial statements$121,136$135,024

Total fees paid to auditors$121,136$135,024

NZX Disclosures

Rua has not applied for nor relied on any NZX waivers during the financial year ended 30 June 2026.

89Rua Bioscience ― Annual Report 2026
Hei konei ra mo tenei wa,

tena koutou i tautoko i

tenei kaupapa, i tenei

kamupene.

9090
Nga mokamoka o te kamupene

Contact directory

Company Number

6484092

Registered Office

Rua Bioscience Limited

704 Te Araroa Road, RD3, Ruatoria 4083

Phone: 0800 RUABIO (782 246)

Share Registrar

Computershare Investor Services Limited

Level 2, 159 Hurstmere Road,

Takapuna, Auckland 0622

Phone: +64 (9) 488 8700

Website

ruabio.com

Facebook

facebook.com/ruabioscience

Instagram

instagram.com/ruabioscience

LinkedIn

linkedin.com/company/rua-bioscience

Directors

Anna Stove

Panapa Ehau

Teresa Ciprian

Tony Barclay

Chief Executive Officer

Paul Naske

Auditors

PricewaterhouseCoopers

Solicitors

Lowndes Jordan

Anderson Lloyd

Contact directory

ruabio.com

Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.